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Summary 
Striated muscle adapts its structure, size, and metabolism to changes in functional demand. This 
is in part communicated by neural and mechanical input. While the events downstream a neural 
impulse have been characterised in depth, little is known about the role of mechanotransduction 
in the regulation of muscle size and metabolism. In mice and humans, muscle disuse induces 
atrophy, while hibernating mammals largely maintain muscle mass. To understand the 
intramuscular changes that prevent atrophy during this period, I analysed the changes in muscle 
of hibernating grizzly bears using high-throughput proteomics and RNA-Seq. The changes in 
protein expression indicate an effect on muscle metabolism, consistent with increased non-
essential amino acid levels and a decrease in ATP production. Supplementing murine myotubes 
with non-essential amino acids increased cell size, suggesting that increased availability of non-
essential amino acids in muscle during hibernation helps prevent atrophy in bears. Comparing 
gene regulation in hibernation to several atrophy-inducing conditions in mice and humans 
identified a set of genes that might contribute to the bear’s specific ability to prevent the loss 
of muscle mass. For two of these genes, Pdk4 and Serpinf1, the effect on atrophy signalling 
was validated in murine myotubes. This supports the utility of the hibernating bear in 
identifying novel regulators of muscle size. 
Towards understanding the role of the sarcomeric mechanotransducer titin in growth signalling 
and metabolism, I studied transcriptional and proteomic changes in C2C12 myoblasts 
expressing the titin kinase domain and an animal model deficient in this domain. The kinase 
domain suppresses Akt activation, possilbly via p62, a protein that interacts with titin’s kinase 
domain and affects signalling upstream of Akt. On the other hand, the titin kinase domain 
activates Nf?B signalling in skeletal muscle by stimulating the processing of p105 to p50, and 
altering p52-RelB transcription, affecting both the canonical and non-canonical pathways. 
Changes in Pdk4, Serpinf1 and insulin signalling in hibernating muscle support the relevance 
of metabolic regulation and signalling molecules to the bears’ ability to preserve muscle mass 
during periods of prolonged disuse or calorie restriction. While titin kinase-dependent 
regulation of pathways that are affected in disuse or exercise indicates a role for this 
mechanically activated domain in regulating muscle adaptation. Thus, both models 
complement our knowledge of molecular adaptations in muscle with insights into the function 
of different signalling molecules, which could serve as targets for the improved treatment of 
muscle disease.
Zusammenfassung 
Die quergestreifte Muskulatur kann ihre Masse und Stoffwechsel an den funktionellen Bedarf 
anpassen – unter anderem über neuronale und mechanische Einflüsse. Während die neuronalen 
Mechanismen gut verstanden sind, ist nur wenig über den Zusammenhang zwischen der 
Mechanotransduktion und der Regulation von Muskelmasse und Stoffwechsel bekannt. In 
Maus und Mensch führt der reduzierte Gebrauch von Muskeln zu Muskelatrophie. Im 
Gegensatz dazu findet man bei Säugern im Winterschlaf in der Regel keine Reduktion von 
Muskelmasse. In der vorliegenden Studie habe ich Veränderungen im Muskel von Grizzlybären 
im Winterschlaf mittels Hochdurchsatz Proteomanalyse und RNA-Sequenzierung untersucht, 
um Rückschlüsse auf intramuskuläre Veränderung zu ziehen, welche Atrophie verhindern. Die 
assoziierten metabolischen Veränderungen, beeinflussen die Verfügbarkeit nicht-essentieller 
Aminosäuren im Muskel. Eine Behandlung von murinen Zellen mit nicht-essentiellen 
Aminosäuren führte zu einer Zunahme der Muskelgröße und deutet darauf hin, dass im 
Winterschlaf eine erhöhte Synthese von nicht-essentiellen Aminosäuren im Muskelgewebe die 
Atrophie reduziert. Die Regulation weiterer Gene im Vergleich zu Atrophie in Maus und 
Mensch ausschließlich während des Winterschlafes deutet auf ihre spezifische Rolle bei der 
Konservierung von Muskelmasse im Grizzly-Bären hin. Die Funktion zweier dieser Gene, 
Pdk4 und Serpinf1, wurde in murinen Myotuben validiert und unterstreicht die Relevanz des 
Winterschlaf-Tiermodells bei der Identifizierung von Genen, die Muskelgröße regulieren. 
Zum besseren Verständnis des Mechanosensors Titin in der Regulation von 
Wachstumssignalen und Stoffwechsel habe ich Veränderungen im Transkriptom und Proteom 
von C2C12 Myoblasten, welche die Titin Kinasedomäne überexprimieren, und einem 
Tiermodel, bei dem diese Domäne fehlt, untersucht. Die Titin Kinasedomäne reduziert Akt 
Aktivierung – möglicherweise über p62, einem Protein, das mit der Titin Kinasedomäne 
interagiert und Signaltransduction über Akt beeinflusst. Weiterhin aktiviert die Titin 
Kinasedomäne den Nf?b Signalweg in dem Skelettmuskel durch die Modulation von p105, p50 
und die veränderte p52-RelB Transkription und aktiviert sowohl den kanonischen als auch den 
nicht-kanonischen Signalweg. 
Akt und Nf?B Signalwege sind abhängig von Muskelaktivität reguliert, was für eine Rolle der 
mechanisch aktivierten Titin-Kinasedomäne in der Homöostase des Muskels spricht. 
Veränderungen in der Signaltransduktion im Muskel über Pdk4, Serpinf1 und Insulin während 
des Winterschlafs zeigt, wie relevant die Regulation von Stoffwechsel und Muskelwachstum 
für den Erhalt der Muskelmasse ist. Die identifizierten Wachstumssignale könnten eine 
ähnliche Rolle in Lebewesen spielen, die keinen Winterschlaf halten – beispielsweise bei 
reduzierter Kalorie-Zufuhr und Immobilisation. 
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1 Abstract 
Mechanotransduction plays an important role in the regulation of muscle growth and metabolic 
signalling in striated muscle. Muscle disuse reduces mechanical input to the muscle, which 
results in a loss of muscle mass. Here I describe how titin's mechanically activated kinase 
domain affects muscle growth and metabolism via p62 and Akt signalling. I also demonstrate 
how changes in metabolic and growth signalling in hibernating grizzly bear help maintain 
muscle mass under conditions that induce muscle loss in humans and mice. I validated some of 
these changes in murine myotubes demonstrating that increasing non-essential amino acid 
levels, increasing Pdk4 levels or suppressing Serpinf1 has a positive effect on growth signalling 
that extends to non-hibernators. 
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2 Introduction 
2.1 Adaptability 
The ability of living species to survive under various environmental conditions emerges from 
the adaptability of biological systems. Adaptability here means the ability of a system to 
regulate its components in response to changes in the environment with which it interacts. This 
property is key in keeping organisms functional despite changes in temperature, nutrient 
availability and predator behaviour for example. The ultimate goal is for the organism to be 
able to sustain its own existence and procreate despite alterations in external stimuli. In 
unicellular organisms, the survival of a species in a new environment could simply be brought 
down to the individual cells' ability to produce enough energy under the current circumstances 
to sustain the next cell division even if at the expense of the less fit counterparts. At a 
multicellular level, it is slightly more complicated, especially as each cell type starts to serve a 
different purpose, all of which contributes to the general fitness of the organism. The challenge 
then becomes sustaining the whole organism, while preserving each cell type or the organ it 
comprises without much damage (Gardner, 2009). This has led to the emergence of centralized 
control in higher animals such as mammals, who exert central regulation largely through the 
brain. Central regulation helps coordinate the response of the various organs to changes in 
environmental stimuli, while each organ is hard wired to attempt preserving itself in the 
process. 
2.2 Muscle tissue 
In vertebrates myocytes are the cells that build up muscle tissue, and their characteristic 
property is the ability to contract, changing their shape and area, facilitating organ locomotion. 
This is possible due to the presence of a network of actin and myosin filaments that utilize ATP 
to produce force. All muscles are under neural control, which regulates how they respond to 
changes in the environment ensuring concerted action. Some muscles are under voluntary 
control such as skeletal muscle, while the heart and smooth muscle which lines, among other 
organs, the internal viscera are not. Together cardiac (heart) and skeletal muscle is referred to 
as striated muscle owing to the distinct striated pattern they exhibit under a microscope. This 
striated pattern comes from the organization of their contractile machinery into distinct units, a 
property smooth muscles lack. 
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Figure 1 : Structure of striated muscle. 
(a) Striated muscle is composed of bundles of myofibres, which are themselves made 
up of myofibrils. Myofibrils consist of sarcomeres which are constituted of a 
network of structural proteins intricately arranged to allow muscle contraction. (b) 
Skeletal muscle cells are formed by the fusion of several individual cells during 
development, giving rise to elongated, multi-nucleated cells. (c) Cardiac muscle 
cells are interdigitated mono-nucleated cells, smaller in size than skeletal muscle 
cells. (Adapted from Junqueira’s Basic Histology Text and Atlas)  
2.2.1 Striated muscle 
Skeletal muscle is made of fibres (cells) arranged in series or parallel to form the whole muscle. 
The number and arrangement of these fibres determines how fast and strong a muscle 
contraction is. These fibres are themselves made of smaller contractile units called myofibrils 
which come together in bundles of 500-10,000 to form one fibre (Figure 1a). The myofibril is 
an assembly of thousands to millions of smaller contractile units called sarcomeres, which are 
arranged in series and considered the smallest force-generating units within striated muscle 
(Figure 1.a). Under the electron microscope a sarcomere can be seen as a structure of alternating 
light and dark bands, where the light bands are regions of actin-containing thin filaments and 
the dark bands regions where actin interacts with myosin-containing thick filaments. The light 
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bands are referred to as I-bands because they are optically isotropic, while the dark bands are 
anisotropic and therefore called A-bands. However, the sarcomere is not only comprised of thin 
and thick filaments. Titin molecules span the half sarcomere, with their N-terminus anchored 
at the Z-disc a structure that separates every two adjacent sarcomeres and also docks the thin 
filaments. The area in the A-band that is slightly lighter than its surroundings is known as the 
H-zone and is where the thick filaments extend in the absence of actin. Within the H-zone is 
the M-line, a thin region where the Titin molecules spanning each half of the sarcomere overlap 
and where only myosin tails and no heads are present (Clark et al., 2002). 
Though both cardiac and skeletal muscle have a similar striated pattern, reflecting the highly 
organized structure of their contractile machinery, they express different isoforms of contractile 
proteins and are functionally different. Isoform expression varies depending on the 
developmental stage, muscle type and muscle load and optimize each type of muscle for its role 
in the body at that particular time or condition. Faulty isoform expression is the base of various 
myogenic diseases (Clark et al., 2002). 
 Skeletal muscle 
During development a skeletal muscle fibre arises from the fusion of several smaller cells, 
which is why they appear cylindrical and are multinucleated (Figure 1b). Each fibre is separated 
from the other by connective tissue and is innervated (Figure 1a). Fibres that are innervated by 
the same nerve contract together and are considered one motor unit. Contraction in a skeletal 
muscle occurs when the neurotransmitter acetylcholine is released from a nerve's end, changing 
transmembranal voltage which generates an action potential (AP). This ultimately leads to the 
release of Ca2+ from its intracellular store in the muscle, a specialized compartment known as 
the sarcoplasmic reticulum (SR). The release of Ca2+ synchronizes various intracellular events, 
including actin-myosin binding which facilitates muscle contraction. Skeletal muscle fibres 
consist of three main types; I, IIa and IIb. Fibre type composition differs between muscle types 
and can change in response to changes in muscle use and load (Schiaffino and Reggiani, 2011). 
Fibres differ largely in their contraction speed and energy source. Type I fibres are rich in 
mitochondria, but relatively poor in glycogen, making them incapable of rapidly generating 
large amounts of glycogen-derived ATP, but nevertheless capable of generating higher amounts 
of ATP overall through fatty acid-driven oxidative phosphorylation. This makes them ideal for 
the slow and stable muscle contractions required to support muscle function over long periods 
of time. On the other hand, type IIa fibres have comparatively less mitochondria, but contain 
more glycogen than type I fibres. This makes them capable of producing sustainable amounts 
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of ATP via oxidative phosphorylation, but also capable of rapidly producing ATP through 
glycogen breakdown and anaerobic respiration. These fibres are thus ideal for supporting 
relatively long periods of intense muscle use, such as required by runners. The third fibre type 
is type IIb, which constitutes fibres that are poor in mitochondria, but generate ATP rapidly 
from the breakdown of glycogen-derived glucose; they are highly fatigable and generate a lot 
of lactic acid. This makes them ideal for fast responses, but not long-lasting ones. The three 
fibre types also express different isoforms of contractile molecules to match their contractile 
abilities (Schiaffino and Reggiani, 2011). 
 Cardiac muscle 
The mechanism of force generation in the heart is similar to skeletal muscle but cardiac 
structure and cellular composition is somewhat different. Because the heart is constantly 
beating, cardiac muscle cells (cardiomyocytes) are rich in mitochondria, and ATP production 
is sustained primarily through fatty acid oxidation. Glycogen is also present, but in low amounts 
(Stanley, 2005). Unlike skeletal muscle fibres that are long and multinucleated (Figure 1b), 
cardiomyocytes are smaller and much easier to distinguish as individual cells (Figure 1c). 
Adjacent cells interdigitate holding the heart together as a well-connected mesh; and the 
membrane between them is organized into distinct gap-junction-rich regions called 
intercalated-disks (Clark et al., 2002). These low resistance areas facilitate the rapid transfer of 
an action potential from one cell to the next, a key property for a well-functioning heart. This 
ability of cardiac cells to relay an action potential throughout the heart, together with the 
presence of specialized auto-excitatory cells makes the stimulus for contraction inherently 
different from skeletal muscle. Unlike skeletal muscles, which need innervation for the 
generation of an action potential and subsequent contraction, cardiac cells can synchronize their 
beating in response to locally-generated action potentials, making innervation unnecessary for 
each and every cell. Only certain parts of a cardiac muscle are extensively innervated to regulate 
the rate of cardiac contraction in response to external stimuli (Zaglia et al., 2013; Shen and 
Zipes, 2014). 
2.2.2 Striated muscle and the adaptation in size 
Striated muscle size changes in response to alterations in their load and frequency of use (Alway 
et al., 1988). This is evident in the increase in skeletal muscle size in athletes with consistent 
training. Once an athlete stops training, their muscle size is no longer put to stringent use and 
their skeletal muscle size decreases to within the average range (Faulkner et al., 2008). 
Similarly, the hearts of hypertensive patients exhibit left ventricular hypertrophy to compensate 
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for the increased resistance in the blood vessels through which the heart needs to pump 
oxygenated blood.  Although compensatory at first, this increase in size often becomes 
pathological and increases mortality among hypertensive patients (Berenji et al., 2005). Such 
is an example of a situation where controlling adaptational changes in striated muscle is 
necessary. Similarly, decreased use and/or load is the reason why immobilized patients often 
suffer from skeletal muscle loss as do astronauts in space (Glass, 2003). Muscle size also 
declines in aging and malnourished individuals, as well as cachectic and spinal cord injury 
patients (Thuret et al., 2006). Characterizing the pathways that control muscle growth and 
adaptation can thus help prevent undesired changes in muscle size, minimizing mortality in 
some cases and improving the quality of life of patients in others. 
2.2.3 Striated muscle and metabolism 
Together, the heart and skeletal muscle constitute about 40% of an average individual's body 
weight. They contribute to 30% of the body's resting energy consumption, and almost 100% of 
it during exercise (DeFronzo and Tripathy, 2009; Baskin et al., 2015). Skeletal muscle is also 
the major site of postprandial glucose uptake (80%), and is where most of the body's glycogen 
is stored under resting conditions. This makes striated muscle important in regulating blood 
glucose levels and whole-body metabolism, and its failure to do so can be of consequence on 
the whole body. For example, skeletal muscle, together with adipose tissue, was found to be an 
important contributor to the development of diabetes in some genetically prone populations 
(Pratipanawatr et al., 2001). Studies on normal glucose tolerant offspring of type II diabetic 
parents in these populations have shown that the skeletal muscle of the asymptomatic children 
was often insulin resistant long before they developed the full blown symptoms and that the 
children were glucose tolerant mostly because of a compensatory increase in B-cell insulin 
release. The children who failed to increase B-cell insulin secretion where those that were most 
likely to develop diabetes later on in life (DeFronzo and Tripathy, 2009). In a reverse type of 
interaction, some diabetic patients develop diabetic cardiomyopathy, a heart condition that 
involves left ventricular hypertrophy, systolic and -in 30-60% of cases- diastolic dysfunction 
(even after correction for age, hypertension, obesity, hypercholestrolemia and coronary heart 
disease) (Boudina and Abel, 2007). Part of the pathoetiology is attributed to the changes in the 
heart's metabolic machinery during diabetes, where there is a reduction in the mitochondrial 
enzymes required for oxidative phosphorylation, decreasing the heart's ability to efficiently 
produce ATP from FAs, its major energy source (Boudina and Abel, 2007). Thus striated 
muscle is affect by and is important for maintaining metabolic homeostasis (Baskin et al., 
Introduction 
 
7 
2015). This has made the study of metabolic control in striated muscle a topic of interest not 
only to muscle biologists but to many of those interested in metabolic diseases. 
2.2.4 Molecular regulation of skeletal muscle size and metabolism 
Several pathways have been implicated in the orchestration of both metabolic and trophic 
changes in response to increased muscle utility, including Ca2+-CaM-CaMK, PI3K-AKT-
mTOR and NFKB signalling (Glass, 2003). All these signalling pathways work in part by 
facilitating changes in the expression of genes that alter metabolism and the rates of protein 
turnover in response to different stimuli. 
 Ca2+-CaMK signalling 
Ca2+ release is a critical step in the response of striated muscle to an action potential as it binds 
to TroponinC allowing crossbridge formation, which is necessary for muscle contraction. Ca2+ 
is not only important in muscle, but is a ubiquitous secondary messengers in all cell types and 
its intracellular concentration is altered in response to various stimuli (Clapham, 2007). The 
specificity of the calcium response is coded in the amplitude and periodicity of the Ca2+ waves 
propagated through the cytosol, which is generated in a stimulus-specific manner (Berridge et 
al., 2003). In muscle, an action potential changes membrane potential increasing Ca2+ influx 
into the cell via voltage sensitive channels. These receptors are also coupled to Ryanodine 
receptors (RyR) along the sarcoplasmic reticulum (SR), the major compartment for Ca2+ 
storage in a muscle cell (Figure 2). This enhances the rise in cytoplasmic Ca2+ levels. Also the 
binding of Acetylcholine (Ach) to the muscarinic Ach receptors or of catecholamines to the ?1-
adrenergic receptor induces the formation of IP3, which activates IP3R channels another Ca2+ 
channel along the SR membrane (Fill and Copello, 2002). Elevated cytoplasmic Ca+2 not only 
binds to Troponin C but many other proteins as well, which allows it to couple changes across 
different intracellular processes. One class of Ca2+-binding proteins is Calmodulin (CaM) 
which acts as a Ca2+ receptor that binds many other proteins and regulates their function in a 
Ca2+-dependent manner. These proteins include kinases, phosphatases and nucleotide 
phosphodiesterases (Means, 2000). One of the better studied families of CaM-binders are the 
Ca2+/Calmodulin-dependent kinases (CaMK), a family of 4 kinases that mediate intracellular 
events in response to changes in intracellular Ca2+ concentrations. The kinases of this family 
are grouped into four classes: the Myosin Light Chain Kinases (MLCK) and the CaMKI, 
CaMKII and CaMKIV kinases. 
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Figure 2 Neurotransmitter-mediated Ca2+-signalling in striated muscle. 
Activated muscarinic or ?1-adrenergic G-protein coupled receptors activate 
phospholipase C which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds IP3R on the 
sarcoplasmic reticulum (SR) enhancing the release of Ca2+. Cytosolic Ca2+ mediates 
muscle contraction, Ca2+ release from the ER and activates calmodulin (CaM), 
which in turn activates CaMKII. Active CaMKII phosphorylates HDAC5, 
preventing its nuclear localization, while activating histone deacetylases P300/CBP 
by phosphorylating Serine (S) 133, counteracting the effect of HDAC5 in the 
nucleus. This enhances the expression of the glucose transporter GLUT4 while 
suppressing atrogene expression. CaMKII can also inhibit P300/CBP activity by 
phosphorylating S143. 
While MLCK almost exclusively associate with actomyocin to phosphorylate the myosin light 
chains (MLC), the other three families have various targets ranging from cytosolic to membrane 
and nuclear proteins (Means, 2000). CaM-binding leads to a conformational change in these 
kinases, displacing their autoinhibitory domain to expose the catalytic core. This leads to their 
activation and allows subsequent substrate binding. Unlike the other CaMKs, CaMKII 
functions as a multimeric complex of 10-12 subunits. These are encoded by 4 different genes 
in mammals, expressed and spliced in a tissue-specific manner. The binding of CaM to two 
adjacent subunits not only induces the conformational change necessary for the activation of 
the other CaMKs but also promotes the phosphorylation of the adjacent subunit, making its 
subsequent activity Ca2+-independent until dephosphorylated (Means, 2000). In striated muscle 
CaMKII is the main CaMK family expressed and its phosphorylation increases in skeletal 
muscle of humans and rats in response to acute training (Rose and Hargreaves, 2003). This 
observation suggests it plays an important role in regulating muscle adaptation to use. Not much 
Introduction 
 
9 
is known about the consequence of this enhanced activity, but the inhibition of CaMKII in 
skeletal muscle inhibits contraction-mediated glucose uptake, but not that stimulated by insulin 
(Witczak et al., 2010). This can be explained by CaMKII’s ability to increase GLUT4-vesicle 
fusion at the membrane, increasing glucose uptake. Exercise-induced CaMKII activation 
however seems to have no consequence on glycogen breakdown rates, but could affect GLUT4 
expression levels (Ojuka et al., 2012). More functions of CaMKII in the muscle adaptive 
response can be envisioned based on the function of some of its known targets, among which 
are the Class II histone deacetylases (HDAC) HDAC4 and 5. These HDACs play an important 
role in muscle growth and metabolic regulation (Moresi et al., 2010; Karpac and Jasper, 2011) 
and their nuclear localization is  phosphorylation-dependent (Karpac and Jasper, 2011). HDAC 
phosphorylation promotes their nuclear export and cytosolic sequestration by 14-3-3 proteins 
thereby preventing them from regulating gene expression (Figure 2) (McKinsey et al., 2000). 
HDAC5 inactivation decreases atrogene expression, preventing muscle wasting and enhancing 
muscle growth (Moresi et al., 2010). It also increases glucose uptake, glycogen synthesis, 
mitochondrial respiration and ATP production in skeletal muscle (Raichur, 2012; McGee, 
2014). Thus an increase in CaMKII activity upon muscle use could inhibit HDAC-mediated 
atrogene expression and enhance energy production, thereby helping the muscle adapt to this 
increase in demand. CAMKII also phosphorylates the histone acetyltransferases (HATs) CBP 
and P300, which counteract the activity of HDACs; an event that activates them if 
phosphorylation takes place on ser133, but inhibits them if ser142 is phosphorylated (Means, 
2000). Moreover, the over expression of various CaMKII isofroms in the hearts of mice leads 
to changes in cardiac muscle size and function, demonstrating their importance in maintaining 
these processes in the heart (Anderson et al., 2011). 
 PI3K-Akt-mTOR signalling 
The PI3K-AKT-mTOR signalling cascade is the pathway downstream of insulin (INS) and the 
insulin-like growth factors (IGF) (Figure 3). Upon INS/IGF binding, the receptors dimerize and 
cross phosphorylate one another, which enhances their kinase activity. This results in a tyrosine 
phosphorylation of the insulin receptor substrates (IRS1-6), which function as adaptor proteins 
that relay the signal to downstream effectors. These effectors include the regulatory subunit of 
PI3K (p85), which leads to the activation of the catalytic subunit and the generation of 
phosphatidylinositol 3-phosphate (PIP3) which serves as a binding platform for proteins with 
a pleckstrin homology (PH) domain (Taniguchi et al., 2006). One of the most well studied PH-
containing proteins recruited to the membrane and activated downstream of INS/IGF signalling 
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is Protein kinase B (AKT). This protein is phosphorylatable at two amino acids both of which 
lead to its activation. Phosphorylation at Thr-308 is catalysed by another PH-containing kinase, 
PDK1 which is also recruited to the membrane upon INS/IGF binding; and Ser-473 which is 
catalysed by the RICTOR-mTOR-containing mTORC2 complex (Sarbassov et al., 2005). 
When activated, AKT regulates many other proteins such as GSK3B which inhibits glycogen 
synthesis; mTOR, which regulate rates of protein synthesis, AS160 a GTPase-activating protein 
that mediates GLUT4-vesicle transport to the membrane and FOXO1 which - when 
unphosphorylated and deacetylated - activates the transcription of gluconeogenic and muscle-
specific ubiquitin ligases (Manning and Cantley, 2007) (Figure 3). 
Figure 3: Insulin/Insulin-growth factor signalling in striated muscle. 
IGF/INS binding to receptor tyrosine kinases (RTK) induces phosphorylation and 
activation. This recruits IRS, which in turn activates PI3K, catalysing the generation 
of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). AKT and PDK1 move to the 
membrane. PDK1 and mTOR phosphorylate AKT, contributing to its activation. 
Active AKT activates the TORC1 complex, which is upstream of S6K and 4EBP1, 
both involved in protein synthesis. AKT also inhibits FOXO transcription factors 
upon phosphorylation and inhibits their nuclear import, where they are deactylated 
by HDAC5 to activate atrogene expression. AKT enhances glucose uptake via 
GLUT4 and inhibits GSK3-beta activity. This enhances glycogen synthesis via 
glycogen synthase (GYS). AKT activation also helps set in a negative feedback loop 
by activating GRB2 which mediates ERK1/2 phosphorylation. The ERKs inhibit 
IRS by its phosphorylating a serine. 
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While HDAC phosphorylation is CaMK-dependent, FOXO1 deacetylation is HDAC-
dependent (Mihaylova et al., 2011) suggesting that FOXO1 might serve as an integration node 
for signals from different pathways (Karpac and Jasper, 2011). AKT has three isoforms which 
are very homologous, but expressed at different ratios in different tissues, and have relatively 
different functions (Taniguchi et al., 2006). In muscle both AKT1 and AKT2 are present, but 
AKT3 is mostly neuron specific. While AKT1 has been linked to the regulation of cell growth, 
AKT2 has been shown to affect intracellular metabolism to a greater degree (Taniguchi et al., 
2006). Another of the important IRS binding proteins is GRB2, which plays an important role 
in activating the MAPK pathway leading to changes in cellular growth, division and 
differentiation (Taniguchi et al., 2006). The MAPK signalling components ERK1/2 can inhibit 
IRS activity by serine phosphorylation and so play a role in insulin-mediated glucose 
metabolism (Taniguchi et al., 2006). Indeed studies in muscle show that cardiac and skeletal 
muscle hypertrophy are associated with an increase in AKT phosphorylation as well as that of 
its downstream targets, and is prevented by inhibiting mTOR-mediated protein synthesis (Stitt 
et al., 2004). Others show that insulin resistance in diabetic patients' muscle is associated with 
a decrease in mitochondrial oxidative phosphorylation, which again links metabolic changes in 
muscle to changes in insulin signalling (Patti et al., 2003). Exercise can decrease muscle 
glycogen content independent of insulin activity and in MIRKO mice (a muscle-specific 
knockdown of the insulin receptor) insulin-mediated glucose uptake and glucose-6-phosphate-
dependent glycogen synthase activation in muscle is decreased (Wojtaszewski et al., 1999). 
However, these mice are more capable of increasing glucose uptake and glycogen synthase 
activity in response to exercise suggesting the possibility of an exercise-dependent, insulin-
independent regulation of glucose uptake and glycogen synthase activity that cross-talks to 
insulin in some way. 
 NFKB signalling 
NFKB signalling has long been implicated in inflammation, tumorigenicity and development 
(Gilmore, 2006). Its components include the NFKB transcription factors (TF), their inhibitors 
the IKB and the IKB- inhibitors the IKKs. The NFKB transcription factor family consists of 
several proteins, all of which contain a Rel homology domain that allows DNA binding and 
protein dimerization (Gilmore, 2006). The differences in the c-termini of these transcription 
factors splits them into two main subfamilies: the Rel subfamily which comprises RelA (p65), 
RelB and c-Rel; and the NFKB subfamily which comprises p100 and p105. The Rel subfamily 
have poorly conserved c-terminal transactivation domains, while the NFKBs are characterized 
Introduction 
 
12 
by their long c-terminal domains that inhibit their TF activity until degraded (Gilmore, 2006). 
In vivo, all the NFKB TFs can form homo- or heterodimers, except for RelB which only form 
heterodimers. The NFKB TF dimers bind to 9-10 base-pair long DNA stretches known as kB 
sites of variable nucleotide composition. Each dimer has its own binding site preferences, 
making this family capable of regulating a myriad of complex transcription responses (Gilmore, 
2006). When bound to the IKB proteins, NFKB transcription factors are inhibited, and are 
mainly cytosolic (Figure 4).  
Figure 4: Canonical and non-canonical NFKB signalling. 
(a) Extracellular stimuli that activate the canonical NFKB pathway induce the 
phosphorylation of IKKs, leading to the phosphorylation, ubiquitination and 
degradation of IKB. This allows p65-p50 heterodimers to move to the nucleus where 
they are transcriptionally active. (b) Other stimuli lead to the activation of NIK, 
which phosphorylates IKK-alpha, which in turn phosphorylates the c-terminus of 
the IKB p100. This leads to the ubiquitination and degradation of the c-terminus of 
p100, releasing the transcriptionally active p52-RelB heterodimer, which then 
translocates to the nucleus and initiates transcriptional changes. LT-Beta, 
lymphotoxin-Beta. Adopted from (Oeckinghaus et al., 2011). 
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However, in response to stimuli the IKB kinases (IKK) are activated, phosphorylating the IKB 
proteins which increases their ubiquitination and targets them for degradation (Oeckinghaus et 
al., 2011). P100 and p105 are also considered to be IKB proteins, the inhibitory domain of 
which is processed in response to stimuli to release the functional p52 and p50 TFs. The 
efficiency of p100 processing to p52 is dependent on p105 and p105 proteolysis is in part also 
dependent on p100 (Y?lmaz et al., 2014). NFKB signalling is involved in disuse skeletal muscle 
atrophy independent of a local inflammatory stimulus or obvious cytokine activity (Hunter et 
al., 2002). Nuclear p50 as well as Bcl3 are both elevated in the muscle of unloaded limbs in 
mice, which results in a 10 fold increase in NfkB reporter activity (Hunter et al., 2002). This is 
independent of RelA and p52 which are both unchanged in the unloaded hindlimbs or RelB 
which decreases in unloaded muscle. P105 and Bcl3 knockout mice are both resistant to disuse-
induced atrophy (Hunter and Kandarian, 2004). On the other hand, Ikka and RelB regulate of 
skeletal muscle metabolism, as knockouts of either gene have lower mitochondrial content and 
are less capable of oxidative respiration, increasing the glycolytic type IIb fibres (Bakkar et al., 
2012). These changes are mediated via a RelB-dependent decrease in Pgc1-? levels, which in 
turn lead to a decrease in mitochondrial gene transcription and abnormal mitochondrial 
biogenesis.  
 Mechanical input 
In the previous sections I mentioned examples of how muscle use affects glucose uptake and 
glycogen synthesis in an insulin-independent manner and how disuse has been reported to 
enhance Nf?b signalling without obvious involvement of inflammatory players. Such findings 
and others pose a question as to how a muscle communicates information about its use or disuse 
to the intracellular signalling pathways controlling glucose uptake, glycogen synthesis and 
Nf?b signalling. One possibility is the activity-dependent release of Ca2+. With both 
denervation and disuse, neural input to the muscle is absent/reduced, thus the AP-dependent 
increase in cytosolic Ca2+ is suppressed, and so are all the subsequent Ca2+-dependent signalling 
events. Although evidence for declined neuromuscular activation in space also exist, the 
application of more load (force) on the feet of astronauts has improved muscle wasting 
compared to unloaded astronauts (Layne et al., 1998). This indicates the importance of not only 
neural input in regulating intramuscular changes, but also mechanical input such as force. 
Another observation is that treadmill training of patients with spinal cord injury seems to 
enhance these patients' lower limb abilities despite the absence of supraspinal communication 
(Dietz et al., 1994), also arguing for a role of mechanical input in regulating neuromuscular 
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function. Such findings support the presence of intramuscular sensors of mechanical input. 
These are likely molecules that are responsive to force, undergoing some sort of conformational 
change that is of consequence on the muscle's signalling pathways (Hoshijima, 2006). One such 
candidate is the sarcomeric protein Titin, which contains many spring-like immnoglobulin 
(IgG) and fibronectin type III (FN3) domains important for regulating sarcomere stiffness 
(Linke and Hamdani, 2014) and serve as binding sites for proteins important in muscle growth 
(Linke, 2008). Towards titin’s c-terminus is an autoinhibited serine/threonine kinase domain 
(frequently referred to as titin kinase) that is believed to be inhibited in resting muscle, but was 
shown to unfold its regulatory domain to expose the catalytic domain under physiological force 
ranges (Puchner et al., 2008). This makes it an ideal mechanosensor in muscle because it is 
inhibited during rest and activated in the presence of force. Despite its structural similarity to 
CaMKs, recent reports have indicated that this kinase is a pseudokinase more likely to serve as 
a binding hub for other proteins in response to stretch (Bogomolovas et al., 2014). One such 
protein is the muscle specific E3-ligase Murf1, which is known to bind M-band titin but not 
titin kinase itself (Centner et al., 2001). Murf1 binds titin at a site slightly more N-terminal than 
the titin kinase domain and was shown to bind significantly better in its presence  
(Bogomolovas et al., 2014). This links Titin kinase to protein turnover pathways, and suggests 
the possibility of other similar Titin kinase-dependent binding events at the M-band. Another 
Titin kinase-dependent interaction partner is Nbr1, which localizes at the M-band in a 
mechanically-inducible manner, recruiting the protein P62, which then binds another muscle-
specific E3-ligase, Murf2. This event sequesters Murf2 from translocating to the nucleus and 
degrading its target serum response factor (SRF) a transcription factor that is then rendered 
inactive when the muscle is in use (Lange et al., 2005). A similar effect could be envisioned 
for Murf1, where mechanical contraction allows its binding to TK and prevents it from substrate 
ubiquitination. Indeed, Murf1's substrates include structural proteins such as Telethonin (Tcap), 
Nebulin, Troponin and Myosin light chain 2 as well as metabolic enzymes such as muscle 
creatine kinase, NADH dehydrogenase, pryuvate kinase, pyruvate dehydrogenase-? (PDHB) 
and the mitochondrial ATP synthase beta subunit (Centner et al., 2001). The consequence of 
such an interaction would thus be the preservation of these proteins from degradation to help 
maintain muscle structure and metabolic function. Nevertheless, these are only single examples 
that link titin kinase to intracellular effectors, but the functional effects of titin kinase on muscle 
have yet to be studied. 
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2.3 Hibernation and atrophy resistance 
Despite the detrimental effect of caloric restriction, muscle disuse and denervation on muscle 
size in humans and mice, nature has presented us with models that are largely resistant to this 
phenomenon under similar conditions. Such exceptions are mammals that hibernate for 
prolonged periods every year, a period of caloric restriction and muscle disuse that is not 
accompanied by significant muscle loss. While smaller hibernators such as squirrels seem to 
go through extreme measures to reduce demand on skeletal muscle protein such as reducing 
core temperature to ~0 degrees for stretches at a time to suppress enzymatic function and 
metabolism, bigger hibernators such as the black and brown bears are capable of the same 
despite a mild decrease in body temperature (~ 6 degrees) (Carey et al., 2003). This makes them 
very interesting models for scientists and clinicians interested in understanding how to prevent 
atrophy in human patients (Bodine, 2013). For one thing, hibernating bears reduce whole body 
metabolism to decrease metabolic demand during this time. This is independent from the 
decrease in core body temperature reported during hibernation (Tøien et al., 2011). Also, bears 
compensate for the lack of ingested nutrients by accumulating large amounts of adipose tissue 
before hibernating. During hibernation their adipose tissue becomes insulin resistant alleviating 
insulin's inhibitory effect on lipolysis (Nelson et al., 2014). The result is an increase in 
circulating triglycerides and glycerol which serve as energy alternatives, reducing the demand 
on protein catabolism. They also efficiently reabsorb amino acids in their kidneys allowing 
their recycling into protein (Stenvinkel et al., 2013b). Part of these animals' ability to preserve 
muscle mass despite disuse was also attributed to regular neural stimulation of the muscle, 
which serves as a signal of muscle use. However, even denervated bear muscle is resistant to 
wasting during hibernation (Lin et al., 2012) suggesting that other intramuscular changes must 
be contributing to muscle preservation during this time, not just neural stimulation. Little is 
known about the intramuscular changes in hibernating bears besides findings that suggest that 
transcriptional changes that suppress metabolism, oxidative damage and enhance protein 
synthesis seem to be prevalent at this time (Fedorov et al., 2014). 
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2.4 Aim of the study 
In this thesis I study how mechanical input affects muscle size and function, and how -despite 
its absence- hibernating grizzly bears are resistant to changes in muscle size. This thesis is thus 
split into two parts: the first is concerned with identifying intracellular mechanisms that protect 
grizzly bear (Urus arctos) skeletal muscle from atrophy during hibernation. With this project 
we hoped to identify novel mechanisms nature has adapted to fight muscle loss, and determine 
if they could be beneficial in reducing muscle loss in non-hibernating species. In the second 
part of this thesis I focus on understanding how Titin kinase affects intracellular signalling in 
vivo, shedding light on its previously unknown contributions to intracellular signalling on a 
cellular and organ level. With such knowledge we hope to better understand how exercise, and 
more generally muscle use, communicates to the muscle’s intracellular machinery even in the 
absence of neural input. Such knowledge could help improve the treatment and quality of life 
of patients with debilitating neural injury such as paraplegics as well as of patients suffering 
from metabolic disorders such as diabetes mellitus, both of which have been shown to be 
responsive to increased skeletal muscle stimulation. 
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3 Material and methods 
3.1 Material 
3.1.1 Chemicals and kits 
Chemicals were purchased from GE Healthcare, Invitrogen, Roth, or Sigma-Aldrich if not 
stated otherwise. 
Table 1. Kits. 
Kit Manufacturer 
Supersignal West Femto / Pico Chemiluminescent Substrate Pierce Chemical Co. 
Pierce BCA protein assay kit Thermo 
Bradford protein assay kit Bio-Rad 
PureLink™ Quick Plasmid Miniprep Kit Invitrogen 
PureLink™ HiPure Plasmid Filter Maxiprep Kit Invitrogen 
RNeasy Mini Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
RiboMinus™ Transcriptome Isolation Kit (Human/Mouse) Invitrogen 
Illumina® Total™ Prep-96 mRNA amplification kit Ambion 
Quant-iT™ dsDNA HS Assay Kit Invitrogen 
Illumina® Genomic DNA single end sample prep kit Illumina 
Illumina® Genomic DNA paired end sample prep kit Illumina 
GS FLX Titanium General Library Preparation Kit 454 Life Sciences 
XF Glycolysis Stress Test Kit SeaHorse 
 
3.1.2 Enzymes 
Table 2. Enzymes. 
Enzyme Manufacturer 
DNase I QIAGEN 
Nucleic acid Restriction enzymes NEB 
Taq DNA polymerase Invitrogen 
Trypsin, cell culture grade Invitrogen 
Immobilized Trypsin Applied Biosystems 
LysC Wako 
DNA restriction enzymes NEB 
T4-ligase NEB 
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3.1.3 Oligonucleotides 
Table 3. Primers for cloning. 
Primer Sequence (5’-3’) 
T7TKCD_Fwd TTTTTGATATCACCAGGATGGCATCGATGACAGG 
T7TKCD_Rev AATCAAGGGTCCCCAAACTC 
Fwd: Forward; Rev: Reverse 
Table 4. Primers for genotyping. 
Primer Sequence (5’-3’) 
Neo_Fwd AGAGGCTATTCGGCTATGACTG 
Neo_Rev AGCCATGATGGATACTTTCTCG 
Puro_Fwd CAAAGCATGCATCTCAATTAGTCAGCATGACCGAGTACAAGCCCA
Puro_Rev CAGATTGTACTGAGAGTGCACCATACCAGGCACCGGGCTTGCGG 
Fwd: Forward; Rev: Reverse 
Table 5. Primers and probes for quantitative real-time PCR (qRT-PCR). 
Gene Sequence/Assay Dye/Quencher Company 
Pdk4 Mm01166879_m1 FAM/MGB LifeTechnologies
Serpinf1 Mm00441270_m1 FAM/MGB LifeTechnologies
Actb 4352341E VIC/MGB LifeTechnologies
18S 
rRNA 
4310893E VIC/TAMRA LifeTechnologies
IGF-1 Fwd: 
TGTCGTCTTCACACCTCTTCTACCT 
Rev: CCACACACGAACTGAAGAGCAT 
Probe: 
TCACCAGCTCCACCACAGCTGGAC 
FAM/TAMRA MWG 
Fwd: Forward; Rev: Reverse 
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Table 6. Oligonucleotides for shRNAs. 
Oligo Sequence (phospho-5’-3’) 
shPDK4-693F GATCAGACGCTATCATCTACTTAATCGAGTTTAAGTAGATGAT
AGCGTCTACTTTTTG 
shPDK4-
693R 
TCGACAAAAAAGACGCTATCATCTACTTAAACTCGAGTTTAAG
TAGATGATAGCGTCT 
shSERPINF1-
900F 
GATCTCACCTTCCCGCTAGACTATCCTCGAGGATAGTCTAGCG
GGAAGGTGATTTTTG 
shSERPINF1-
900R 
TCGACAAAAATCACCTTCCCGCTAGACTATCCTCGAGGATAGT
CTAGCGGGAAGGTGA 
F: forward, R: reverse 
 
Table 7 Plasmids. 
Backbone Company 
pTET-OFF CloneTech 
pTRE2 CloneTech 
 
3.1.4 Antibodies 
Table 8. Primary antibodies used for Western blotting (WB). 
Antibody Species Dilution Manufacturer 
Akt Rabbit 1:1000 CST 
pAkt (ser473) Rabbit 1:1000 CST 
Fhl2 Rabbit 1:200 Bethyl 
Gsk3?? Rabbit 1:1000 Millipore 
pGsk3??(ser9) Rabbit 1:1000 Millipore 
Hdac4 Rabbit 1:1000 CST 
Hdac5 Rabbit 1:1000 Abcam 
Nf?B1 Rabbit 1:1000 Sigma 
Nf?B2 Rabbit 1:1000 CST 
Pdk4 Rabbit 1:1000 Abcam 
Pten Rabbit 1:1000 CST 
P62 Mouse 1:200 Abcam 
Serpinf1 Rabbit 1:2000 Abcam 
?-Tubulin Mouse 1:1000 Sigma 
T7 Mouse 1:10,000 Novagene 
 
Material and methods 
 
20 
Table 9. Secondary antibodies and fluorescent-labelled reagents used for Western blotting (WB). 
Antibody Species Dilution WB Manufacturer 
Anti-rabbit IgG HRP-
conjugated 
Goat 1:1000 Sigma-Aldrich 
Anti-mouse IgG HRP-
conjugated 
Goat 1:1000 CalBiochem 
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3.2 Methods 
3.2.1 Cloning 
 PCR amplification 
All PCR amplifications were done using a high fidelity Taq (Invitrogen), on a PeQstar 
2x thermocycler (PeQlab) unless otherwise specified.  
 Nucleic acid digestion 
All nucleic acids were digested with the specified restriction enzymes as follows unless 
otherwise specified: 
Table 10. Test digestion mix. 
Reagent Amount 
Restriction enzyme 0.5 ?l 
BSA 0.5 ?l 
DNA Equivalent of <= 1 ?g
NEB buffer (10x) 5 ?l 
ddH20 To 50 ?l 
Incubate at 37 °C for 1 h   
 DNA ligation 
All ligation reactions were done as follows: 
Table 11. DNA ligation mix. 
Reagent Amount 
T4-Ligase 1 ?l 
Ligase buffer (10x) 2 ?l 
Vector 100 ng  
Insert 5 x Vector (M) 
ddH2O To 20 ?l 
Incubate O.N. at 37 °C   
 Bacterial transformation and plasmid amplification 
Chemically competent DH5alpha E. coli bacteria were used for the transformation of all the 
plasmids generated. 5 ?l of the ligation was added to the DH5alpha competent cells and then 
incubated for 30 min on ice. The bacteria were then heat-shocked at 42 °C for 45 seconds and 
immediately transferred to ice for 2 minutes. 500 ?l of super optimal broth with catabolite 
repression (SOC) medium was then added to the mixture and incubated at 37 °C for 1 hour 
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while shacking at 600 rpm. The mixture was then transferred to Luria Broth (LB) -agar plates 
containing either Ampicillin (Sigma; 100 ?g/ml) or Kanamycin (Sigma; 50 ?g/ml), and left to 
dry before incubation at 37 °C overnight. The next day clones were picked and incubated in 5 
ml of liquid-LB medium with the corresponding antibiotic. Plasmid DNA was then isolated 
using a DNA miniprep kit (Qiagen) for subsequent use. For greater amounts of DNA, bacteria 
were they were cultured in 200 ml of liquid-LB and DNA isolation was done using Qiagen's 
Maxiprep kit as per the manufacturer's instructions.  
SOC medium 
2% tryptone (Roth), 0.5% yeast extract (BD Biosciences), 10 mM NaCl (Roth), 2.5 mM KCl 
(Roth), 10 mM MgCl2 (Roth), 10 mM MgSO4 (Roth), and 20 mM glucose (Roth).  
LB-Agar 
171. ?M NaCl (Roth), 1% tryptone (BD Biosciences), 0.5% yeast extract (BD Biosciences), 
1.5% agar (BD Biosciences). 
Liquid LB 
171.1 ?M NaCl (Roth), 1% tryptone, 0.5% yeast extract (BD Biosciences). 
 DNA plasmid quality control 
All plasmids generated were test digested to ensure the success of the ligation and subsequently 
sent for sequencing. Validated plasmids were then amplified and isolated using a maxi-prep kit 
(Invitrogen) as per the provider's instructions. DNA concentration was determined using a 
Nanodrop ND-1000. 
 DNA agarose gel electrophoresis 
Unless specified otherwise, DNA molecules were resolved on a 0.8% UltraPure ™ agarose 
(Invitrogen) gel in 0.5x Tris-acetate-EDTA (TAE) buffer in the presence of Ethidium bromide 
to allow visualization upon ultra violet (UV) exposure. Gels were poured into a casting tray 
and left polymerize. Gels were then transferred to an electrophoresis chamber (Cosmo Bio Co) 
containing TAE, after which DNA samples were mixed with loading buffer at a ratio of 1:5 
and loaded. Fragments were separated at 100 V for 20 minutes before visualization on a Gel 
Doc 2000 UV transilluminator (BioRad).  
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0.5 x TAE buffer 
20 mM Tris-base, 0.05% acetic acid, 0.5 mM EDTA pH 8.0 
Loading buffer 
0.5% orange G, 50% glycerol, 25 mM EDTA pH 8.0 
 pTetOff-TKCD plasmid: 
T7-tagged TKCD was PCR amplified from a pre-existing plasmid (pCGT7-TKCD) using 
T7TKCD_Fwd and T7TKCD_Rev primers. The following program was used for amplification 
on a PTC-225 thermal cycler (MJ research): 
Table 12. PCR program for amplification of TKCD. 
Temperature °C  Time (s) 
95 5 
Start loop   
95 20 
50 30 
72 90 
End loop   
Repeat loop 30 x  
72 600 
8 Hold 
 
The amplification products were resolved on a 0.8% Agarose gel, after which they were 
extracted and kit purified from the agarose gel (Qiagen). They were then digested together with 
1 ?g of the pTRE2-puro plasmid (Clontech) with EcoRV and BamHI in NEB buffer 3.  
The digest PCR product was then ligated into the digested pTRE2-puro plasmid at a molar ratio 
of 5:1. 
 shRNA expression plasmids: 
The sequence of the shRNAs used were determined based on entries in the RNAi consortium 
database (https://www.broadinstitute.org/rnai/public). Constructs with the highest efficiency 
and least off-target effects were chosen and synthesized with a 5'-phosphate group and BglII/ 
XhoI restriction overhang on each of the forward and reverse oligos respectively. 
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Oligos were mixed as in table 13 after which they were incubated first at 95 °C for 1 minute 
then in a beaker of boiling water and left to cool in it overnight. This allows for their annealing 
to form the final double-stranded (ds) shRNA construct. 
Table 13. ds-shRNA construct annealing mix. 
Reagent Volume 
Fwd_shRNA 
oligo 
Equivalent of 20 uM
Rev_shRNA oligo Equivalent of 20 uM
NEB buffer 2 (10 
x) 
5 ul 
ddH2O To 50 ul 
  
The ds-shRNA constructs were then ligated into pSUPER-Retro-puro (Oligoengine) that was 
digested with XhoI and BglII in NEB buffer 3.1. Minipreped plasmid DNA was then test 
digested with XhoI and SacII in NEB CutSmart buffer. 
3.2.1.8.1 Genotyping C2C12-TetOFF/pTRE2-T7-TKCD stable cell lines 
Cells were lysed in RIPA buffer after which 10 ?l was used for genotyping. Cells were 
genotyped for the incorporation of the pTetOFF plasmid using primers for the Neomycin 
resistance gene (NeoR; Neo_Fwd/Rev primers) and for the pTRE2-T7-TKCD plasmid using 
primers for the Puromycin resistance gene (PuroR; Puro_Fwd/Rev primers) according to the 
following PCR program: 
Table 14. PCR program for NeoR/PuroR amplification. 
Temperature (°C)  Time 
(s) 
95 5 
Start loop   
95 20 
50 30 
72 90 
End loop   
Repeat loop 34 x  
72 600 
8 Hold 
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3.2.2 Cell culture 
Cells were maintained and passaged in Dolbecco's Modified Eagle's Medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 5% of 1x penicillin and 
streptomycin (P/S) solution (Invitrogen). The aforementioned medium is referred to as growth 
medium throughout the following sections. For passaging, cells were washed in 1 x phosphate 
buffered saline (PBS; diluted from 10x PBS; Lonza) before they were trypsinized in 0.2% 
Trypsin solution (Invitrogen) for 5 minutes. Trypsinization was stopped by adding growth 
medium, after which the appropriate number of cells were seeded for passaging.  
 DNA transfection 
DNA was transfected into cells using PEI40 (40 kD poly-(ethylene imine); Polysciences 
Europe GmbH) complexed with DNA at a ratio of 6 mg PEI40: 1 mg DNA. The total volume 
of DNA was always 10 ?g and when two plasmid was transfected at a time, 5 ?g of each was 
used.  
 Generating Tet-OFF Titin kinase-expressing C2C12 cells 
C2C12 cells were grown to 80% confluence on a 10 cm dish before they were transfected with 
the pTet-OFF vector (CloneTech). 48 h post-transfection, medium was changed to G418-
sulphate selection medium (600 ?g/ml of growth medium) and maintained under selection until 
single clones remained (~10 days). Individual clones were picked and expanded independently. 
A single clone of those genotyped to be positive for the Neo-marker was selected and 
transfected with the pTRE2-T7-TKCD plasmid described above. Selection was done in 
Puromycin-dihydrochloride (50 ?g/ml growth medium, Calbiochem). Dox induction was done 
using 5 ?g/ml of Dox dissolved in DMSO (Sigma). Controls were treated with DMSO only.  
 Generating shRNA-expressing C2C12 cells 
ShRNA constructs were transferred to C2C12 cells via viral infection to enhance the efficiency 
of DNA delivery, as C2C12 cells are relatively difficult to transfect at a high efficiency with 
PEI40. In this case, Phoenix cells were grown to ~ 80–90% confluency and 10 ml fresh growth 
was added before transfection. 30 ?g plasmid DNA was mixed with 62.5 ?l 2 M sterile CaCl2 
(Roth) and the volume brought up to 500 ?l with ddH2O. Using a pipette, air was bubbled 
continuously through 500 ?l of 2X HEPES buffered saline to which the DNA-CaCl2 mixture 
was added dropwise. The mixture was incubated for 5 min at room temperature and added 
dropwise to a 10 cm plate of Phoenix cells. To increase the transfection efficiency, 11 ?l of 
25 mM chloroquine (Sigma-Aldrich) was also added to the cells. 24 h after transfection, the 
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medium was changed to 6 ml fresh growth medium and 48 h post transfection 6 ml of virus-
containing supernatant was collected and filtered through a 0.45 ?m syringe filter before 
transferring onto a 50% confluent 10 cm dish of C2C12 cells. 16 ?l of polybrene (Sigma-
Aldrich; 4 mg/ml) was added to increase the infection efficiency. After removal of the viral 
supernatant, Phoenix cells were washed with 1X PBS before addition of 4 ml fresh growth 
medium. C2C12 cells were infected a second time 6 h later by transferring 4 ml of fresh viral 
solution to the previous round's. 24 h after the first infection, the viral solution was removed 
from C2C12 cells and two more infection steps were performed. C2C12 cells were thus infected 
a total number of four times to obtain a higher infection efficiency. The infected cells were 
subsequently selected with puromycin-dihydrochloride (50 ?g/ml, Calbiochem) for one week 
before use and were subsequently kept under selection at all times.  
 C2C12 cell differentiation 
C2C12 cells were grown to ~90% confluence in growth medium before switching to 
differentiation medium. Differentiation medium was similar to the normal growth medium 
except that the 10% FBS was replaced with 2% horse serum (HS; Sigma). Cells were kept in 
differentiation medium for at least 8 days, and the medium changed every 2 days in between.  
 Insulin induction of C2C12 cells 
Cells were kept for 8-12 h in serum-free medium containing 0.2% sterile-filtered BSA. 
Induction was then done using 6 ?g/ml of human Insulin (PAN biotech). Cells were then 
incubated for a minimum of 5 minutes and maximum of 30 minutes, after which cells were 
washed in PBS and immediately lysed in RIPA buffer on ice.  
 Dexamethasone treatment of C2C12 cells 
Differentiated C2C12 cells were treated with 10 ?M dexamethasone-acetate (Sigma) in DMSO 
(Sigma) in 2% HS medium for 2 days. Controls were treated with DMSO only. 
 Non-essential amino acid supplementation of C2C12 cells 
Differentiated C2C12 cells were treated with 10 x non-essential amino acid (NE-AA) solution 
(Gibco) in 2% HS medium for 2 days and compared to non-treated cells. 
 Secreted protein preparation and Igf-1 quantification 
C2C12 cells were seeded on 15 cm dishes in 25 ml of growth medium until they reached 80% 
confluence. Medium was then changed to 0.2% BSA-containing DMEM and cells were 
incubated in it for 8-12 hours before 10 ml of the medium was transferred to 15 ml Falcon 
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tubes. The supernatant was spun down once at 200 rpm to pellet debris, then the debris-free 
supernatant was transferred to a fresh Falcon and snap frozen in liquid nitrogen. The 
supernatant was later concentrated on a 3 kD, 15 ml Amicon centrifugatl filter for protein 
concentration as per the manufacturer’s instructions. The concentrated protein was then used 
to measure the amount of secreted Igf-1 using an ELISA kit (Peprotech) as per the 
manufacturer’s instructions. 
 Metabolic function measurement in C2C12 cells 
C2C12 cells were seeded at a density of 70,000 cells/well on a 24-well XFe24 cell culture micro 
plate (SeaHorse) one day before they were analysed on a XFe24 analyzer (SeaHorse). The 
following day the cells were processed as per the manufacturer’s instructions for the 
measurement of metabolic function using the XF Glycolysis stress Test Kit (SeaHorse). Data 
was analysed using the provider’s software and Excel (Microsoft). 
 Cell size quantification 
Myotube quantification was adapted from a method described previously (Sandri et al., 2004). 
In short, at least 20 random bright field images were taken at 20 x magnification and 
subsequently imported into and analyzed in ImageJ by measuring the thickness of the widest 
area across myotubes of similar morphology. In each group 20±5 cells were used for 
quantification. 
3.2.3 Animal procedures 
 Grizzly bear samples 
(Conducted by Dr. L. Olson, Washington State University, USA) 
Four grizzly bears were used for this study: an adult, a subadult and 2 cubs. All animals were 
housed at the Washington State University Bear Research, Education and Conservation Center. 
The animals were maintained according to the Bear Care and Colony Health Standard 
Operating Procedures approved by the Washington State Institutional Animal Care and Use 
Committee (IACUC) based on the US National Institutes of Health guidelines. Hibernation 
began the first week of November when feeding ceased, and ended the second week of March 
when feeding resumed. Water was available ad libitum, and straw was provided for bedding 
during hibernation. Bears hibernated in pairs in unheated pens (3 x 3 x 2.5 m3) with continuous 
access through a small door to an outdoor area (3 x 5 x 5 m3).  Because the dens were open to 
the outside, the bears experienced daily light and temperature fluctuations. The dens and runs 
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were monitored with surveillance cameras (Silent Witness) which confirmed that bears were 
recumbent for 98% of the hibernation period. The bears were anesthetized with tiletamine HCl 
and zolazepam HCl (5 mg/kg during the active phase and 2 mg/kg during hibernation) 
administered intramuscularly by air dart. Isoflurane in 100% oxygen was administered via 
endotracheal tube to maintain a constant plane of anaesthesia for muscle biopsies. The bears 
were judged to be in an adequate plane of anaesthesia based on lack of response to the mild 
stimulus caused by instrumentation, lack of jaw tone and lack of a palpebral reflex. The lateral 
surface of the leg over the gastrocnemius muscle was shaved, prepped and a sterile field was 
maintained. An incision (~4 cm in length) was made over the gastrocnemius muscle to excise 
small biopsies (approximately 1 x 1 x 2 cm3). The biopsies were immediately frozen in liquid 
nitrogen and subsequently stored at –80 °C until analysed. 
 Mouse samples 
(Conducted by Dr. M. Radke, Max Delbrück Centre, Berlin, Germany) 
3.2.3.2.1 Sciatic nerve lesion 
Denervation was performed as described in (Moresi et al., 2010). In brief, adult mice were 
anesthetized with isoflurane. The sciatic nerve of the left leg was exposed and a 2 mm piece 
was removed. The right leg remained innervated and was used as a control. Mice were 
sacrificed and the gastrocnemius muscle dissected and quickly frozen in liquid nitrogen 2 and 
14 days after denervation. 
3.2.3.2.2 Endurance running test 
Adult male mice were trained on a custom-built running belt for 30 days, 5 days a week at a 
speed of 23 cm/s. In the 1st week animals were trained for 20 min, in the 2nd week the training 
time was increased by 5 min per day up to 45 min. Animal tissues were harvested one day after 
the last exercise.  
3.2.4 mRNA expression 
 RNA extraction and cDNA synthesis for qRT-PCR: 
C2C12 cells were washed twice in PBS after which 300 ?l of RTL buffer (Qiagen) was added, 
followed by subsequent extraction using an RNeasy mini kit (Qiagen). RNA was subsequently 
quantified on a NanoDrop ND-1000 (Thermo-Scientific). 0.7-1 ?g of RNA was equally used 
for all the samples in one run and reverse transcribed into cDNA using a high capacity RNA-
to-cDNA kit (Applied Biosystems) as follows: 
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Table 15. RNA to cDNA reverse transcription mixture. 
Reagent Volume (?l) 
RNA Equivalent of 1 ?g
RT buffer 10 
RT enzyme 1 
RNAse-free water To 20 
 
The above mixture was then incubated on a PeQSTAR 2x thermocycler (PeQlab) with the 
following program: 
Table 16 Thermocycler program for RNA reverse transcription. 
Temperature (°C) Time (min) 
37 60 
95 5 
8 Hold 
 qRT-PCR 
All qRT-PCR assays were run using the TaqMan technology from Applied Biosciences on an 
ABI-7900 HT. Each biological replicate was pipetted in triplicates and assays were performed 
using the TaqMan® gene expression master mix (Applied Biosystems) as follows unless stated 
otherwise: 
Table 17. TaqMan gene expression master mix for qRT-PCR. 
Reagent Volume 
(?l) 
cDNA (7-10 ng) 1 
TaqMan gene expression master mix 5 
Endogenous control 0.5 
Gene expression assay (Primer/probe 
pairs) 
0.5 
Nuclease-free water (Ambion) 3 
  
 C2C12 expression profiling using microarrays 
RNA was extracted from C2C12 cells as mentioned above and three biological triplicates for 
each condition were pooled. The RNA quality was evaluated on a 2100 Bioanalyzer (Agilent). 
To reduce ribosomal RNA (rRNA) we used the RiboMinus Kit (Invitrogen). Biotinylated 
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cRNA was prepared using the Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion) 
according to the manufacturer's directions starting with ?100 ng total RNA. Expression 
profiling was performed using Illumina’s MouseRef-8 v2.0 Expression Bead chip. 
 Grizzly bear expression profiling using RNAseq 
(AG Chen, Max Delbrück Centre, Berlin, Germany) 
3.2.4.4.1 Full-length enriched cDNA library construction and normalization 
The construction of normalized full-length-enriched cDNA libraries for 454 sequencing 
requires three steps: (1) the synthesis of double stranded cDNA using a modified RACE 
technique, (2) the subsequent removal of poly(A):T tails using the methylation sensitive type 
II restriction enzyme GsuI, followed by the ligation of a new DNA adaptor, and (3) the 
normalization of the resulting cDNA library using duplex-specific nuclease (DSN) (Shagin et 
al., 2002; Zhulidov et al., 2004).  
3.2.4.4.2 454 FLX titanium sequencing 
The normalized cDNA library was quantified using the Quant-iT dsDNA HS Assay Kit 
(Invitrogen). A total of 5 mg was used to prepare the sequencing library with the 454 GS FLX 
Titanium General Library Preparation Kit according to the manufacturer’s manual. The 454 
library was then sequenced 200 cycles on a 454 GS FLX sequencer according to the 
manufacturer’s manuals.  
3.2.4.4.3 Single-end cDNA sequencing using Illumina GAIIX 
5 μg of full-length cDNA was used to construct a single-end sequencing library using the 
Illumina Genomic DNA Single End Sample Prep kit according the manufacturer’s manuals. 
The DNA concentration was measured with a Nanodrop 7500 spectrophotometer, and a 1-mL 
aliquot was diluted to 10 nM. Adaptor-ligated DNA was hybridized to the surface of flow cells, 
and DNA clusters were generated using the Illumina cluster station, followed by 50 cycles of 
sequencing on the GAIIX, in accordance with the manufacturer’s protocols.  
3.2.4.4.4 Paired-end RNA-Seq using Illumina GAIIX 
A total of 300 ng of poly(A) RNA was fragmented at 94 °C for 3.5 min using 5 x fragmentation 
buffer (200 mM Tris-Acetate at pH 8.1, 500 mM KOAc, 150 mM MgOA) in a total volume of 
20 ml. The fragmented RNA was precipitated and converted to first-strand cDNA using 
Supescript II (Invitrogen), followed by second-strand cDNA synthesis with E.coli DNA pol I 
(Invitrogen) and RNase H (Invitrogen). Then the paired-end sequencing library was prepared 
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using the Illumina Genomic DNA Paired End Sample Prep kit according the manufacturer’s 
manuals. The DNA concentration was measured with a Nanodrop 7500 spectrophotometer, and 
a 1-mL aliquot was diluted to 10 nM. Adaptor-ligated DNA was hybridized to the surface of 
flow cells, and DNA clusters were generated using the Illumina/ Illumina cluster station, 
followed by 2 x 76 cycles of sequencing on the GAIIX, in accordance with the manufacturer’s 
protocols. 
5 x fragmentation buffer 
200 mM Tris-Acetate at pH 8.1, 500 mM KOAc, 150 mM MgOA. 
3.2.4.4.5 De novo transcriptome assembly 
The 454 reads were assembled using Newbler 2.3 (Roche) with default parameters. The 
Illumina assembly comprised of Illumina paired-end reads was obtained by using the 
SOAPdenovo software (Li et al., 2010) (http://soap.genomics.org.cn) with default parameters. 
Contigs longer than 100 bp in the Illumina assembly were combined together with 454 reads 
for the final assembly using Newbler with default parameters.  
3.2.4.4.6 Transcriptome annotation 
Out of 43599 transcripts, 22641 were aligned to the human protein database 
(Ensembl version 66) using BLAST with e-value ? 1E-10, corresponding to 9768 human 
proteins.  
3.2.4.4.7 Differential transcript expression 
Single-end Illumina reads were aligned to transcripts using SOAP2 allowing at most 2 
mismatches to estimate the expression of each transcript. Transcripts corresponding to a total 
of 4783 genes were aligned. NOISeq (Tarazona et al., 2011) was then used to estimate the 
likelihood of differential expression (probability > 0.8 considered differential).  
 Mouse RNA preparation for microarray-based expression profiling 
(Dr. M. Radke and AG Huebner, Max Delbrück Centre, Berlin, Germany) 
Skeletal muscle and cardiac left ventricular tissue was homogenized with a homogenizer in the 
presence of TRIzol (Invitrogen), extracted with chloroform, precipitated in ethanol, and 
dissolved in nuclease-free water. After quality control (2100 Bioanalyzer, Agilent) and DNAse 
digestion, RNA was purified using Rneasy columns (Qiagen) and stored at –80°C. To reduce 
ribosomal RNA (rRNA) we used the RiboMinus Kit from Invitrogen. Biotinylated skeletal 
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muscle cRNA was prepared using the Illumina® TotalPrep™-96 RNA Amplification Kit 
(Ambion) according to the manufacturer's directions starting with ?100 ng total RNA. 
Expression profiling was performed using Illumina’s MouseRef-8 v2.0 Expression Bead chip. 
Cardiac biotinylated cRNA was prepared from 10 ?g total RNA using the SuperScript Choice 
System from Invitrogen and the Affymetrix T7-(dT)24 primer, which contains a T7 RNA 
polymerase promoter attached to a poly-dT sequence. Following a phenol/chloroform 
extraction and ethanol precipitation, the cDNA was transcribed into biotin-labelled cRNA using 
the Retic Lysate IVT™ kit (Ambion). cRNA products were then purified using an RNeasy kit 
(Qiagen) and fragmented to an average size of 30-50 bases according to Affymetrix 
recommendations. 15 ?g of the fragmented cRNA was used to hybridize the Mouse Genome 
430 2.0 Array for 16 h at 45°C.  
 Analysis of gene expression profiling data 
Illumina chips were quantile normalized without background subtraction in Genome Studio’s 
Gene Expression module version 1.9.0. Genes with an expression p-value of less than 0.05 in 
all samples were retained for subsequent analysis, while all others were discarded. Affymetrix 
chips were analyzed using AltAnalyze v.2.0.6 (Emig et al., 2010) with default parameters 
making further processing unnecessary.  
3.2.4.6.1 Denervation data 
8 samples were used for comparison in the analysis: GA muscle after 2 and 14 days and the 
contralateral innervated leg for each animal. Samples were available for three WTs and KOs in 
each group. For each gene the average value in the control leg was calculated, and used to 
normalize the value of the gene in the corresponding denervated leg. This reduces the 
complexity of the data from 8 to 4 triplicates. The effect of denervation and genotype were then 
determined based on a Two-way Analysis of Variance analysis (TWA).  
3.2.4.6.2 Trained animal data 
The expression values of each gene in the three trained WT and KO samples were normalized 
to the average value in the three untrained animals of the same genotype. A t-test was done to 
compare genes that were regulated between the trained KOs and WTs.  
3.2.4.6.3 C2C12 data 
Since the returned values per gene in this experiment was already an average of three pooled 
biological replicates of TK-expressing and TK-null cells, a t-test was not appropriate. Instead, 
the fold change in gene expression values for each gene was calculated and found to follow 
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normal distribution. With the assumption that in the presence of TK only a small subset of 
genes will be regulated on the transcriptional level, we considered the majority of genes 
unchanged, and only those with a fold change that falls beyond 2 standard deviations from the 
mean of all genes were considered to be differentially regulated between the two samples.  
3.2.4.6.4 Pre-existing transcriptomic datasets 
For comparison to our own data more models of muscle atrophy were allocated on the GEO 
database. Five GEO datasets were selected for this purpose: GSE674 -Aging, HS (Welle et al., 
2003), GSE8872 -Ankle fracture, HS (Chen et al., 2000), GSE21496 - Unloading, HS (Reich 
et al., 2010), GSE25908 - Casting, MM (Bialek et al., 2011) and GSE24504 - Fasting, MM 
(Hakvoort et al., 2011). Since dataset GSE24504 lacked the associated CEL files, for 
consistency, all datasets were analysed using GEO2R for differential gene expression. GSE674 
gene expression levels from young women aged between 20-29 years (n = 7) were compared 
to those aged 65-71 years (n = 8). Genes were considered differentially expressed at p-value < 
0.01. As for GSE8872, the immobilized (casted) legs from ankle fracture patients were 
compared to the contralateral leg as controls (n = 4). Significance was considered at p-value < 
0.01. In case of GSE21496 the 48 h unloading samples were normalized to the 0 h unloading 
samples as controls (n = 7). Significance was considered at p-value < 0.01. For GSE25908, the 
14-day casted legs (right) were compared to the left control legs from the same mouse (n = 9). 
Genes were considered significantly regulated if the Benjamini-Hochberg-corrected p-value (p. 
adj) was < 0.05. Finally, for GSE24504, muscle samples after 72 h of fasting were compared 
to the controls at 0 h (n = 5). Significance was considered at p. adj < 0.05.  
3.2.5 Meta-analysis of global gene expression during atrophy 
To help identify genes that play a role in muscle atrophy across the different species under 
different atrophy-inducing conditions, a meta-analysis with a total of seven datasets was 
conducted. All data sets were compared using their Official Gene Symbols. Since the data come 
from different platforms (RNA-seq, Illumina and Affymetrix), comparing the FCs across the 
datasets could be misleading and contributes little information to our purpose. Thus 
directionality of regulation was only considered and FCs were discretized as follows:  
??? ?
?? ? ?? ???? ? ??
?? ? ?? ???? ? ?
???????????????????????????? ???? ? ?
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where FC is the ratio of mRNA in the treated group normalized to the control and FCd is the 
discretized FC. Only genes that were identified in RNA-seq and spotted on the chips were 
included in the analysis. Genes were then grouped as follows: Regulated in hibernation only if 
the gene is regulated only during hibernation and none of the other datasets; regulated during 
hibernation and other conditions if the gene is regulated during hibernation and at least half of 
the other datasets; not regulated in hibernation but in other atrophy-conditions if the gene is not 
changed during hibernation but regulated in at least half of the other datasets.   
3.2.6 Guilt-by-association functional inference  
Co-expressed genes were determined using the software GeneFriends (van Dam et al., 2015), 
which queries a vast set of RNAseq datasets for genes that are often coexpressed (either 
increased or decreased) with the input gene list. Genes increased or decreased during 
hibernation only were used as input gene lists for the algorithm. The resulting list of co-
expressed genes were filtered for a p-value ? 0.01, then only the genes that were associated 
with ?5 genes in the input lists were considered and utilized for functional annotation using a 
KEGG pathway enrichment analysis.  
3.2.7 KEGG pathway enrichment analysis 
All analyses were done using the CLUEGO plugin in Cytoscape (Bindea et al., 2009; Shannon 
et al., 2003). Kappa-score threshold was always set to 0.3, min. % genes to 0 and min. number 
of genes to 2. P-values were Benjamini-Hochberg corrected for multiple testing and denoted 
(p-adj.).  
3.2.8 Transcription factor binding site (TFBS) enrichment analysis 
This analysis was done to determine the TFBSs that are enriched in the promoter region of the 
genes regulated two and 14 days post-denervation. Based on the results of the TWA described 
above, genes regulated based on genotype were further filtered for those regulated at each of 2 
and 14 days post-denervation between WT and KO samples. The regulated genes (p<0.05) were 
then used as an input set for the web-based application DAVID (Huang et al., 2008). As 
background we used the whole array of genes spotted on the chip. Functional annotation using 
only protein_interactions > UCSC_TFBS as a term was performed to return information about 
the TFBSs enriched and the genes downstream of them. TFBSs were considered enriched if 
assigned a Benjamini-Hochberg-adjusted p-value of <0.05.  
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3.2.9 Protein expression 
 C2C12 protein lysate preparation for western blotting 
C2C12 cells were lysed in RIPA buffer containing PhosStop phosphatase inhibitor (Roche) and 
Complete EDTA-free protease inhibitor (Roche), then treated with Benzonase (Sigma) to digest  
DNA and facilitate pipetting. Samples were then incubated on an elliptical rotor at 4 °C for 1 h 
before subsequent use. Protein lysate was subsequently quantified using a BCA assay kit 
(Thermo). In preparation for immunoblotting, samples were mixed in 4 x Laemmli buffer and 
boiled for 5 minutes before use.  
RIPA buffer 
150 mM NaCl, 1 % NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0) 
4x Laemmli buffer 
277.8 mM Tris-HCl, pH 6.8, 4.4% LDS, 44.4% (w/v) glycerol, 0.02% bromophenol blue; 355 
mM ?-mercaptoethanol.  
 Polyacrylamide-gel electrophoresis 
Stacking gel was always poured at a 5% polyacrylamide percentage while the resolving 
polyacrylamide gels of  between 15-10% were used, depending on the size of protein of interest. 
Gels were assembled and run in a Quatro mini-protean electrophoresis cell (BioRad) with 1x 
running buffer. Equal amounts of 50-100 ?g of protein were loaded per sample together with 
7 ?l of PageRuler™ Prestained Protein Ladder (Fermentas). After proteins were appropriately 
resolved, the were transferred to a nitrocellulose membrane (Amersham) in a mini-trans blot 
cell (BioRad) at 200 V for 2 h. Successful protein transfer was determined by staining the 
membrane in Panceau S after which membranes were subsequently destained in TBS-T. 
Blocking was done in 5% BSA (in PBS) and membranes were incubated with the respective 
1ry antibody (Ab) overnight at 4 °C. Membranes were washed in TBS-T before incubation with 
the Horse radish peroxidase (HRP)-conjugated 2ry Ab for 2 hours at RT. Membranes were then 
washed in TBS-T and developed using supersensitive HRP substrate solution (Pierce) and 
signal was detected and documented using the FUSION-FX7 chemiluminescence detection 
system (PeQlab).  
TBS 
50 mM Tris-HCl, 150 mM NaCl, pH 7.4 
Material and methods 
 
36 
TBS-T 
TBS, 0.1% Tween 20, pH 7.4 
 Densitometry for relative protein quantification 
Band intensity on the images of the exposed membranes was quantified in ImageJ. The intensity 
of the protein of interest was always compared to that of ?-tubulin as a loading control across 
samples.  
 Total murine protein sample analysis by mass spectrometry 
(Dr. M. Radke and AG Kempa, Max Delbrück Centre, Berlin, Germany) 
3.2.9.4.1 Sample preparation for LC-MS/MS 
An in vivo SILAC-approach was used for protein quantification by mass spectrometry. Muscle 
samples dissected from age-matched WT and KO mice were immediately frozen in liquid 
nitrogen then ground using a cooled mortar and pestle. As reference, the muscle of a 129-female 
mouse fed with heavy 13C6-Lysine was used. Labelling efficiency in this mouse was above 
96% as previously determined by LC-MS/MS. 5 mg of sample was re-suspended in urea buffer 
and sonicated for 30 seconds with 2 pulses at 60% power (Sonoplus HD2070). After 
centrifugation to remove debris, protein concentration was measured by a Bradford 
colorimetric assay and 50 ?g of protein was mixed with an equal amount of reference heavy 
sample.  The disulfide bridges of proteins were then reduced in 2 mM DTT for 30 minutes at 
25 °C and successively free cysteines alkylated in 11 mM iodoacetamide for 20 minutes at 
room temperature in the dark. LysC digestion was then performed by adding 2 ?g of LysC 
(Wako) to the sample and incubating it for 18 hours under gentle shaking at 30 °C. The samples 
were then diluted three times with 50 mM ammonium bicarbonate solution, 7 ?l of immobilized 
trypsin (Applied Biosystems) were added and samples were incubated 4 hours under rotation 
at 30 °C. 18 ?g of the resulting peptide mixtures were desalted on STAGE Tips (Rappsilber et 
al., 2003) and the eluates dried and reconstituted to 20 μl of 0.5 % acetic acid in water. 
Urea buffer 
8 M Urea, 100 mM TrisHCl, pH 8.25  
3.2.9.4.2 LC-MS/MS analysis 
5 ?l were injected in duplicate on a UPLC system (Eksigent), using a 240 minutes gradient 
ranging from 5% to 45% of solvent B (80% acetonitrile, 0.1 % formic acid; solvent A= 5% 
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acetonitrile, 0.1% formic acid). For the chromatographic separation a 30 cm long capillary (75 
μm inner diameter) was packed with 1.8 μm C18 beads (Reprosil-AQ, Dr. Maisch). On one 
end of the capillary, nanospray tip was generated using a laser puller allowing fretless packing. 
The nanospray source was operated with a spray voltage of 2.0 kV and an ion transfer tube 
temperature of 260 °C. Data were acquired in data-dependent mode, with one survey MS scan 
in the Orbitrap mass analyzer (60000 resolution at 400 m\z) followed by up to 20 MS\MS scans 
in the ion trap on the most intense ions. Once selected for fragmentation, ions were excluded 
from further selection for 45 seconds, in order to increase new sequencing events. 
Solvent B 
80% acetonitrile, 0.1 % formic acid 
Solvent A 
5% acetonitrile, 0.1% formic acid 
3.2.9.4.3  Data analysis  
(Supported by AG Kempa) 
Raw data were analysed using the MaxQuant proteomics pipeline v1.2.2.5 and the built-in 
Andromeda search engine (Cox and Mann, 2008; Cox et al., 2011) with the International 
Protein Index Human (version 3.71) database. Carbamidomethylation of cysteines was chosen 
as fixed modification, oxidation of methionine and acetylation of N-terminus were chosen as 
variable modifications. 2 missed cleavage site were allowed and peptide tolerance was set to 7 
ppm. The search engine peptide assignments were filtered at 1% FDR at both the peptide and 
protein level. The ‘match between runs’ feature was enabled, ‘second peptide’ feature was 
enabled, while other parameters were left as default. 
The analysis was followed up by normalizing H/L ratio to the sum of the areas under all peaks 
per animal after correction for errors in sample mixing with the light and heavy label. Proteins 
with peptides counted less than three times in any of the animals were then emitted. A two-
sided Grubbs test was performed for each identified protein within a group to eliminate outliers 
(p<0.05) This was followed by a two-tailed, unpaired t-test to determine significant differences 
in protein levels between the wild type and titin kinase-deficient muscle. 
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 Phospho-murine protein sample analysis by mass spectrometry 
(Dr. K. Raddatz, University of Greifswald, Greifswald, Germany) 
3.2.9.5.1 Preparation of samples for proteome and phosphoproteome profiling 
Hearts from titin kinase KO and control mice were dissected washed in ice cold isotonic NaCl 
solution and snap frozen in liquid nitrogen. Heart tissue was then grinded with liquid nitrogen 
and suspended in lysis buffer (8 M urea, 10 mM sodium fluoride, 2.5 mM sodium 
pyrophosphate, 1 mM ?-glycerol phosphate, 1 mM sodium orthovanadate, 1 mM tris (2-
carboxyethyl) phosphine (TCEP), 1 mM EDTA, and 20 mM HEPES, pH 8.0). The tissue 
suspension was sonicated and free protein thiols were alkylated by addition of iodoacetamide 
to a final concentration of 5 mM followed by incubation for 20 min at room temperature. 
Lysates were clarified by centrifugation (8,700 x g, 15 min) and protein content was quantified 
using a Bradford assay (Bio-Rad). Peptides were obtained by in-gel digestion using trypsin 
(Promega). For enrichment of phosphopeptides, 5 mg of protein mixtures were diluted eightfold 
with 20 mM HEPES, pH 8.0 and digested with trypsin using a protein-enzyme ratio of 20:1. 
Obtained peptides were purified using C18 Sep-Pak cartridges (Waters) and freeze-dried. 
Peptides destined for TiO2-based enrichment were dissolved in buffer A (5 mM KH2PO4, 30% 
(v/v) acetonitrile, pH 2.7) and separated in 15 fractions by strong ion exchange chromatography 
(SCX) with a Resource S SCX column (1 ml column volume, GE) connected to an Äkta Avant 
chromatography system (GE) using a binary linear gradient with buffer B (5 mM KH2PO4, 350 
mM KCl, 30% (v/v) acetonitrile, pH 2.7) at a flow rate of 1 ml/min. Fractions were lyophilized, 
dissolved in 14 ml TiO2-binding buffer (73% (v/v) acetonitrile, 10% (v/v) lactic acid, 2% (v/v) 
TFA) and 100 ?l from a TiO2-stock solution (30 mg / ml Titansphere TiO2 bulk material (GL 
sciences) in 100% acetonitrile) was added, followed by incubation for 20 min at room 
temperature. Samples were centrifuged, beads were washed four times with 80% (v/v) 
acetonitrile, 2% (v/v) TFA and phosphopeptides were sequentially eluted with 5% (v/v) 
NH4OH and 30% (v/v) acetonitrile. For LC-MS/MS phosphopeptides were vacuum-dried and 
resuspended in 1% formic acid, 0.1% HFBA and 7.5% acetonitrile. 
Lysis buffer 
8 M urea, 10 mM sodium fluoride, 2.5 mM sodium pyrophosphate, 1 mM ?-glycerol phosphate, 
1 mM sodium orthovanadate, 1 mM tris (2-carboxyethyl) phosphine (TCEP), 1 mM EDTA, 
and 20 mM HEPES, pH 8.0 
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Buffer A 
5 mM KH2PO4, 30% (v/v) acetonitrile, pH 2.7 
Buffer B 
5 mM KH2PO4, 350 mM KCl, 30% (v/v) acetonitrile, pH 2.7 
TiO2-binding buffer 
73% (v/v) acetonitrile, 10% (v/v) lactic acid, 2% (v/v) TFA 
TiO2-stock solution 
30 mg / ml Titansphere TiO2 bulk material (GL sciences) in 100% acetonitrile 
3.2.9.5.2 Mass spectrometry and spectra analysis 
LC-MS/MS analyses were performed using an EASY-nLCII nanoflow HPLC system coupled 
directly to an LTQ Orbitrap Velos hybrid mass spectrometer (Thermo Fisher Scientific). 
Peptide samples were dissolved in 20 ?l 5% (v/v) acetonitrile, 0.1% (v/v) acetic acid and loaded 
onto a 20 cm-long self-packed C18 (Aeris Peptide 3.6 ?m, pore size 100 Å; Phenomenex) 
analytical column. Gradual elution of peptides was achieved by running a binary linear gradient 
from 1% (v/v) acetonitrile/0.1% (v/v) acetic acid to 75% (v/v) acetonitrile / 0.1% (v/v) acetic 
acid over a period of 46 minutes with a flow rate of 300 nl/min. The MS was operated in data-
dependent mode, automatically switching between full survey scan (m/z 300–1700) with a 
resolution of 30,000 followed by fragmentation analyses of the top). 20 precursors with a 
charge state greater than one. Fragmentation by CID was performed in the linear ion trap with 
an AGC target value of 5 x 104 ions and normalized collision energy of 35%. Precursors were 
dynamically excluded for repeated fragmentation for 30 s for the CID method. 
The raw data files were processed using MaxQuant (version 1.2.2.5) with the integrated 
Andromeda search engine against the reviewed mouse proteome deposited in UniProtKB 
(Swiss-Prot database, 2011-08-15; 16,384 sequences). Trypsin was specified as enzyme and a 
total number of 2 missed cleavages were allowed. Carbamidomethylation of cysteine residues 
was set as fixed modification. Oxidation of methionine, amino-terminal acetylation and 
phosphorylation of serine, threonine and tyrosine were selected as variable modifications. The 
‘requantify’ and ‘match between runs’ options were enabled. For peptide, protein or site-
specific identifications a FDR cut-off of 0.01 was applied. 
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  Grizzly bear protein quantification by mass spectrometry  
(AG Völker, University of Greifswald, Greifswald, Germany) 
3.2.9.6.1 Protein sample preparation of LC-MS 
Tissue samples were frozen in liquid nitrogen and disrupted using a bead mill as described 
earlier (Hammer et al., 2011) with slight modifications.  The powder resulting from the bead 
mill treatment was dissolved in an appropriate volume of sample buffer (8 M urea; 2 M 
thiourea) and sonicated three times for three seconds on ice (Sonoplus HD 2200). After removal 
of insoluble cell debris by centrifugation (15,300 rpm; 1 h; 4 °C) the supernatant, containing 
the soluble cytosolic proteins, was transferred and used for further analysis. Protein 
concentrations were determined by Bradford assay (BioRad).  
Sample buffer 
8 M urea; 2 M thiourea 
3.2.9.6.2 Peptide Sample Preparation 
Two times 4 μg of each protein sample were prepared for tryptic digestion as technical 
duplicates. Thus duplicates were diluted with 20 mM ammonium bicarbonate (ABC) to obtain 
a final concentration of less than 1 M urea, after which they were reduced using 2.5 mM DTT 
(1 h; 60 °C) and alkylated by 10 mM iodoacetamide (30 min; 37 °C). Tryptic digestion (1:50) 
was performed overnight at 37 °C. The digestion was stopped in 1% acetic acid. The peptide 
mixtures were desalted using C-18 reverse phase material (ZipTip ?-C18 Millipore 
Corporation). 
3.2.9.6.3 Mass spectrometry FTICR Analysis 
The resulting peptide mixtures were separated using nanoAcquity UPLC reverse phase column 
(BEH130, C18, 100 ?m - 100 mm) on a nanoAcquity UPLC system (both Waters, Waters 
Corporation) as previously described in (Hammer et al., 2011). MS data were generated using 
a LTQ-FT mass spectrometer (Thermo Electron). For each sample two technical replicates 
were measured. 
3.2.9.6.4 Quantitative Analysis and Protein identification 
(With assistance from AG Völker) 
The raw data from the LC-ESI-MS/MS measurement were imported into the Rosetta Elucidator 
software version 3.3 (Ceiba Solutions) and processed as described in (Thiele et al., 2012) with 
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slight modifications. The following workflow was used: (i) feature detection; (ii) feature 
alignment across all 16 MS runs; (iii) feature identification via SEQUEST database search (via 
Sorcerer build 4.04, Sage-N Research Inc.) against a forward reverse database containing 
human entries obtained from Uniprot; (iv) feature annotation based on protein teller score 
(> 0.95), (v) median normalization using the annotated features, (vi) Filtering for unique 
peptides. The obtained feature intensities were averaged for each sample, summed up to peptide 
and protein intensities. These steps were carried in a visual script within the software 
Elucidator. The obtained protein intensities were exported to Excel for further analysis. 
3.2.9.6.5 Differential protein expression 
Differential protein expression was determined based on results of a two-way ANOVA taking 
age and activity state as factors. Proteins significantly regulated based on activity were used for 
all further analyses (p-value < 0.05). 
3.2.9.6.6 Non-essential amino acid (NEAA) distribution in regulated proteins 
Since the majority of the identified peptides in U. arctos were based on their homology to 
peptides in the H. sapiens database the amino acid composition for each protein regulated 
during hibernation was determined based on the corresponding reference human protein 
sequence (UniProt). The percentage of all NEAA and only those regulated were determined as 
a percentage of the total number of AAs per protein. 
3.2.10 Metabolic modelling 
Condition specific models were constructed from Recon2 as a reference model since not much 
is known about grizzly bear metabolism and how it deviates from metabolism in other 
mammals, while Recon2 is the most exhaustive reconstruction of a mammalian system to date 
(Thiele et al., 2013). Also most proteins were identified based on their homology to human 
counterparts impeding the identification of any bear-specific metabolic enzymes, even if they 
existed. The GIMME algorithm (Becker and Palsson, 2008) within the 
createTissueSpecificModel function in the COBRA toolbox (Schellenberger et al., 2011) was 
used with the biomass reaction as the objective function. Expression data was provided as 0/1 
based on relative changes in expression levels between the 2 conditions compared. If a 
protein/mRNA species was increased in one condition compared to the other it was assigned a 
value of 1 for that condition and 0 for the other, while a value of 1 was assigned for all species 
expressed but unchanged between the conditions. 
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When creating the hibernation and activity-dependent models for U. arctos the expression data 
was provided based on changes in protein levels, while in case of the aging models of H. sapiens 
muscle mRNA levels were used.  
All computations were done locally on a 64-bit machine and optimization was done using a 
CPLEX solver (version 7, Tomlab) in MATLAB.  
3.2.11 Metabolomics 
 GC-MS analysis and sample preparation 
(Dr. M. Radke and AG Kempa, Max Delbrück Centre, Berlin, Germany) 
Frozen muscle tissue was homogenized and 50 mg powder were extracted with 1 ml methanol-
chloroform-water (MCW) (5:2:1/v:v:v) (Methanol LC-MS-grade, Chloroform Reagent Plus ® 
99.8% Sigma-Aldrich) with cinnamic acid as internal standard (Sigma Aldrich). After the 
addition of 500 μl of distilled water, the supernatant was collected and transferred to safelock 
1.5 ml Eppendorf tubes. MilliQ water was added in an amount corresponding to 0.5 of the 
MCW-volume to each muscle sample, then samples were shaken at 750rpm at 4°C for 60 
minutes on a Thermomixer comfort 1.5ml (Eppendorf). This was followed by centrifugation 
for 10 min to separate the polar (top), lipid (bottom) and interface (tissue debris) layers. Polar 
and lipid phase were then dried under vacuum (SpeedVac RVC 2-33 CD plus, Martin CHRIST) 
over night. Dried samples were chemically modified by derivatization as described in (Kempa 
et al., 2007). 
Metabolite analyses were performed with a Pegasus III mass-spectrometer (LECO) equipped 
with an Agilent 6890N gas chromatograph and a VF-5ms column with 30m length and 250 μm 
inner diameter (Agilent). 1 μl of sample was injected into a baffled liner (Gerstel) with a 1:5 
split-ratio under a helium-flow of 1.2 ml/min using a gradient ranging from 70°C to 350°C with 
5 °C/min to 120 °C and 7 °C/min to 350 °C followed by a 2 minute hold time. Scan rates of 20 
Hz and mass ranges of 70-600 Da were used. The GC-MS chromatograms were processed with 
the ChromaTOF software (LECO) as described in (Kempa et al. 2007) and the data matrices 
for relative quantification were generated using the MetMax software (Kempa et al., 2009). 
 Metabolomic data analysis 
For each sample, the area under the peak corresponding to a metabolite was normalized to the 
area under the peak of the added control. A two-sided Grubbs test was performed within each 
group to eliminate outlier values with a p-value <0.05. This was followed by a two-tailed, 
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unpaired t-test to determine significant differences in protein levels between the wild type and 
titin kinase-deficient muscles at levels of basal muscle activity.  
3.2.12 Statistical analysis 
Statistical analysis and data visualization was mostly done in R. While graph generation was 
done using Excel (Microsoft) or GraphPad Prism 5. 
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4 Results 
This study aimed to understand how striated muscle adapts its size and metabolism during times 
of altered demand. Specifically, we studied: 
(1) How hibernating grizzly bears maintain their muscle mass despite a decrease in activity 
and reduced food intake during this period. 
(2) The role of titin kinase as a mechanosensor in mediating muscle mass and metabolic 
signalling. 
The first question was addressed by analysing global changes in mRNA and protein expression 
in the skeletal muscle of four Grizzly bears before and during hibernation. Findings were 
validated in a murine muscle-like cell line (C2C12) to confirm the relevance and adaptability 
of such findings to non-hibernating species. The second question was addressed by generating 
and analysing C2C12 cells that stably expressed the catalytic domain of Titin kinase in a 
doxycycline-dependent manner. Cell culture data was combined and compared to a study done 
on murine striated muscle lacking the catalytic domain of titin’s kinase. The latter included the 
analysis and integration of transcriptomic, proteomic and metabolomic changes in the muscle 
of these animals. This data collectively helped build a more detailed picture about how titin 
kinase affects growth and metabolic signalling in both skeletal muscle and the heart. 
4.1 Changes on the proteomic and transcriptomic level reflect alterations in 
metabolic and signalling pathways during hibernation. 
To identify the proteomic changes occurring in the skeletal muscle of hibernating grizzly bears, 
we extracted proteins from gastrocnemius (GA) muscle biopsies of two cubs, an adult and a 
sub-adult grizzly bear before and during hibernation (October and February respectively; 
Figure 5). Proteins were subsequently identified and quantified using mass spectrometry. Since 
a published grizzly bear genome was not available at the time of the analysis, proteins were 
identified based on their homology to human homologues. Intensities across samples were 
compared by a two-way ANOVA to determine the changes contributed by the activity state 
(active versus hibernating) and/or age (cubs versus adult and sub-adult). The majority of 
proteins identified enriched to terms related to metabolic processes. A significant number of 
the components of the electron transport chain (oxidative phosphorylation) and the TCA cycle 
were regulated based on the activity state of the bears (p-value < 0.05; Figure 6). 
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Figure 5: Experimental layout for the identification and quantification of 
grizzly bear proteome and transcriptome. 
C: cub, SA: subadult, A: adult. 
 
Since proteins of non-metabolic processes were not prominent in the protein analysis, we 
complemented it with a transcriptomic analysis. RNA from the adult and sub-adult biopsies 
used for the proteomic analysis were used for deep sequencing. Again, transcripts were 
annotated based on their homology to human transcripts and those differentially regulated 
between hibernating and active samples were determined using NOIseq (cut-off >= 0.8) 
(Tarazona et al., 2011). A KEGG-pathway enrichment analysis indicated that genes associated 
with a wide variety of intracellular processes were identified on the transcriptional level, 
extending on the proteomic changes (Figure 6c). The mRNAs regulated during hibernation 
included those associated with the insulin signalling pathway, which affects cells size and 
metabolism in other organisms (Manning and Cantley, 2007). Components of the Hif1? 
pathway, which has also been implicated in the regulation of muscle growth and metabolism 
(Ren et al., 2010), were also regulated in hibernation, as were structural proteins that have been 
previously associated with hypertrophic cardiomyopathy (Figure 6c). Only seven genes were 
regulated on both the protein and mRNA level in these datasets (Figure 6a). 
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4.1.1 Transcriptional changes of insulin signalling components could improve insulin-
sensitivity during hibernation. 
As changes in insulin signalling affect organ size (Stitt et al., 2004), I mapped the changes in 
the significantly regulated mRNAs of this pathway to the corresponding human KEGG 
pathway to visualize its overall regulation during hibernation (Figure 7). There was an 
increased production of the more insulin-sensitive insulin Receptor Substrate (Rondinone et 
al., 1997), Irs-1, and a decrease in the less sensitive counterpart, Irs-2. The Irs-1 inhibitor Socs2 
was decreased, while the Irs-1 effectors Grb2 and Pi3k were increased. Further downstream, 
deptor (the mTor inhibitor) was supressed together with a component of Akt’s target 
phosphorylase kinase complex (Phkg1), while Ppp1r3c was increased. Together, these 
transcriptional changes could improve insulin-sensitivity in muscle if maintained on the post-
transcriptional level. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Summary of proteins and mRNAs 
identified in grizzly bear GA muscle. 
(a) Overlap (purple) between the identified proteins 
(blue) and mRNAs (red). Regulated species are 
indicated in lighter colours with 7 genes regulated in 
both datasets (table). (b, c) KEGG pathway analysis 
of proteins and transcripts identified in gastrocnemius 
muscle (GA) with total identified species (light grey) 
and regulated genes (dark grey). 
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Figure 7: Mapping changes in mRNA levels of the insulin signalling components of GA 
muscle during hibernation (adapted from KEGG). Positive regulators of insulin signalling are 
mostly increased (Inc.) on the mRNA levels, while the negative regulators are decreased (Dec.). 
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4.1.2 Metabolic changes in hibernation suggest a change in central glucose metabolism. 
Since components of the TCA cycle and oxidative phosphorylation were significantly enriched 
among proteins regulated during hibernation, we summarized the changes connected to central 
glucose metabolism (Figure 8a). The relative changes in the expression of the 
glycolytic/gluconeogenic enzymes and TCA cycle components were incorporated into a 
pathway diagram (Figure 8b). An increase in a single glycolytic/gluconeogenic enzyme, Gpi, 
was observed, accompanied by a decrease in all the regulated enzymes of the TCA cycle, except 
Ogdh, which was increased. Pdhb and Pdha1 - both components of the pyruvate dehydrogenase 
complex that shuttles pyruvate into the TCA cycle as acetyl-coA - were decreased, while the 
inhibitor of the Pdh complex - Pdk4 - was increased. Taken together, the data suggest that 
components of the aerobic respiratory pathway are decreased on the protein level, supporting 
reports previous reports of decreased of metabolic rates during hibernation in bears (Tøien et 
al., 2011). These were accompanied by changes in the muscle’s capacity to buffer ROS as 
evident by changes in some of the ROS neutralizing genes (Figure 8a). 
Figure 8: Enzymes related to 
glucose metabolism are 
regulated at the protein level 
in skeletal muscle during 
hibernation. 
(a) Summary of changes in 
enzymes related to central 
glucose metabolism in 
hibernation (versus activity) 
that occur irrespective of age 
(p-value < 0.05, two-way 
ANOVA). (b) Pathway of 
central glucose metabolism 
overlaid with hibernation 
associated changes in proteins 
depicted in (a). Proteins in red 
are increased (inc.) during 
hibernation, proteins in blue 
are decreased (dec.). No diff.: 
No difference; NA: not 
applicable. 
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4.1.3 Metabolic changes occur in aging human muscle 
To determine whether the metabolic changes observed in the hibernating grizzly bear muscle 
were specific to this type of muscle disuse, or an adaptation to other environmental conditions 
that affect muscle function and size, we compared hibernation associated changes to a publicly 
available dataset of aging muscle (GSE674). This dataset compares genome-wide changes in 
mRNA levels in skeletal muscle biopsies from 15 women; seven aged between 20 and 29 years 
(younger) and eight between 65 to 71 years (Welle et al., 2003). mRNAs with significantly 
different expression levels between the two age groups associated with several metabolic 
processes (Figure 9a).  
Enzymes involved in central glucose metabolism were decreased on the transcriptional level 
(Figure 9b), and are predominantly involved in the TCA cycle and oxidative phosphorylation 
(Figure 9c). Enzymes important for ROS neutralization were also mostly decreased. Together 
these changes suggest that a decreased metabolic capacity in aging, is accompanied by a 
difference in ROS levels which mediate intracellular damage (Finkel and Holbrook, 2000). 
4.1.4 Metabolic modelling suggests that non-essential amino acids increase in the muscle 
in hibernation and decrease in aging. 
The inconsistent increase in Gpi and Ogdh enzyme levels compared to the other enzymes of 
glucose metabolism during hibernation raised the question whether pathways not primarily 
related to energy production were affected. Both the glycolytic pathway and TCA cycle are 
known to provide precursors for non-essential amino acid (NEAA) synthesis which is needed 
to drive protein synthesis. In hibernation, changes that enhance NEAA synthesis together with 
metabolic suppression could help maintain muscle mass. In the absence of metabolomic data 
on hibernating bear muscle we used a modelling approach to assess if these metabolic changes 
could, in principle, affect NEAA levels during hibernation. Thus, relative changes in protein 
levels between hibernating and active muscle were used to build metabolic models that capture 
the effect of enzymatic changes on metabolite levels. The changes were contextualized with 
respect to the most-comprehensive mammalian metabolic model at the time, Recon2, which 
was constructed based on human-derived data. As we identified only proteins that have human 
homologues, the approximation was considered reasonable. After creating the models of active 
and hibernating skeletal muscle, each was set to maximize the production of the different non-
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essential amino acids or their glycolytic and TCA cycle-derived precursors glycerate-3-
phospate (3pg) and alpha-ketogluterate (?-KG) as shown in Figure 10a. 
Figure 9: Changes in mRNA levels in aging skeletal muscle indicate alterations 
in metabolic regulation. 
(a) KEGG pathways with mRNAs regulated in aging female muscle. In grey are the 
adjusted p-values per term. (b) The majority of metabolism-related transcripts are 
decreased in aging muscle. (c) Transcriptional changes in central glucose 
metabolism in aging muscle. Inc.: increased, Dec: decreased, NA: not applicable. 
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The relative change in the maximum producible levels of each metabolite during hibernation is 
summarized in Figure 10b. While ?-KG steady state levels were predicted to be lower during 
hibernation, the levels of glutamate (Glu), alanine (Ala), glutamine (Gln) and proline (Pro) 
which derive from it were all increased. Arginine (Arg), aspartate (Asp) and asparagine (Asn) 
were unchanged, together with the 3pg-derived NEAAs glycine (Gly) and cysteine (Cys). The 
steady state levels of 3pg itself during hibernation were predicted to be increased, so was serine 
(Ser) for which it also serves as a precursor. Tyrosine (Tyr), which can be derived from 
phenylalanine (Phe) by hydroxylation, was also predicted to be increased during hibernation. 
Two age-dependent models were similarly generated using transcriptional data from young and 
older female vastus lateralis muscle biopsies to assess their impact on NEAA synthesis, and 
compared them to changes in hibernation. Seven NEAAs were predicted to have lower steady 
state levels in aging female muscles. Six of the NEAAs predicted to decrease in aging muscle 
were predicted to increase during hibernation (Figure 10c). 
Figure 10: Metabolic modelling predicts differential regulation of non-essential 
amino acid (NEAA) levels in hibernation versus human ageing. 
(a) Generation of activity-dependent metabolic models. (b) Predicted changes in 
steady state levels of NEAAs and their main precursors in GA during hibernation. 
(c) Prediction of age-dependent changes in NEAA metabolism in human vastus 
lateralis muscle. 
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4.1.5 Increasing NEAA availability increases myotube size in cell culture. 
The results of the metabolic models suggest that intramuscular NEAA levels increase in 
hibernation which is a condition of muscle mass retention, but decreases with age when muscle 
mass is lost. This raised the question of whether NEAAs regulate muscle mass.  
One way NEAAs could enhance muscle mass, is by contributing 50% of the precursors needed 
for protein synthesis. In hibernation NEAAs were predicted to increase, which could selectively 
increase NEAA-rich proteins due to the availability of a larger substrate pool. To test this 
hypothesis, the distribution of NEAA content in the proteins increased versus those decreased 
during hibernation were compared. Although NEAA-rich proteins (> 65% NEAAs) were only 
represented in the proteins increased in hibernation, their number was too low to be statistically 
significant, making the overall distribution across both groups similar (Figure 11a).  
Figure 11: Distribution of non-
essential amino acids (NEAAs) 
in proteins regulated during 
hibernation and their effect on 
myotube thickness. 
(a) NEAA content in the proteins increased 
(red) or decreased (blue) during 
hibernation is not significantly changed 
(mean ± s.d., two-tailed t-test; estimated 
normal distributions of the two populations 
as black and grey dotted lines). (b, c) 
NEAA supplementation significantly 
increases myotube diameter (mean ± s.d., 
t-test). Size bar; 50 ?M. (d) Effect of 
NEAA supplementation on MAFbx levels 
in differentiated C2C12 cells with and 
without Dexamethasone (n=3, mean ± 
s.e.m., two-way ANOVA, Bonferroni 
post-hoc test). Ctrl, control; Dex, 
dexamethasone. 
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It is thus unlikely that NEAA availability affects protein synthesis only by increasing the pool 
of precursors. To test if NEAAs could increase myotube size by affecting cellular process other 
than NEAA-dependent peptide elongation, C2C12 cells differentiated into myotubes were 
supplemented with a commercial solution of NEAA and compared to untreated cells. Upon 
comparison, myotube thickness was significantly greater when cells were supplemented with 
NEAAs (Figure 11b, c). This was associated with a decrease in levels of the muscle-specific 
E3 ubiquitin ligase MAFbx (Figure 11d), which is elevated in atrophic muscle under most 
reported cases (Lecker et al., 2004). These data support the hypothesis that increasing NEAA 
availability could increase muscle size, possibly by affecting the signalling events that control 
MAFbx production. 
 
 
 
 
 
 
 
Figure 12: Differential gene 
expression in hibernating vs. non-
hibernating species identifies 
regulators of skeletal muscle 
atrophy. 
(a) mRNA fold changes during 
hibernation vs. activity in U. 
arctos (top) compared to other 
forms of disues or food-
deprivation (bottom). Italicized 
genes were detected in the 
proteomics dataset. MM, M. 
musculus; HS, H. sapiens; UA, U. 
arctos. (b) KEGG pathways 
enrichment results for the genes 
with which the genes regulated 
during hibernation are most 
commonly expressed. p.adj.: 
adjusted p-value. 
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4.1.6 Identifying atrophy-associated genes by comparing changes in skeletal muscle 
mRNA expression under different atrophy-inducing conditions. 
To identify genes that contribute to the hibernating bear’s ability to resist muscle atrophy under 
caloric restriction and immobilization, we compared changes in mRNA expression during 
hibernation and six other atrophy-inducing conditions. The six conditions affect humans and 
mice, and are associated with a decrease in food intake and/or muscle mobility. The comparison 
was based on the directionality of change under the different conditions and resulted in the 
identification of three main groups of genes (Figure 12a). The first group includes the genes 
regulated during hibernation but in none of the other datasets. These genes were taken to be 
regulated selectively during hibernation, and thus suspected to contribute to the muscle’s ability 
to resist atrophy. The second, smaller group of genes was regulated during hibernation and in 
at least half of the other conditions (similar or opposite direction). The third group contained 
genes that were not regulated during hibernation, but changed in at least half of the other 
datasets. Several of the genes in the three groups have been previously associated with muscle 
size or function. The third group contains genes that are not regulated during hibernation, but 
in at least half of the other datasets. Several of the genes in the three groups have been 
previously associated with muscle size or function (Table 18).  
4.1.7 Validating the effect of Pdk4 and Serpinf1 on atrophy signalling in C2C12 cells. 
To experimentally validate the effect of the genes in group one on atrophy, two were selected 
to be stably knocked down in C2C12 cells using gene-specific shRNAs. The two genes were 
Pdk4, a metabolic enzyme important in shuttling pyruvate into the TCA cycle (Zhang et al., 
2014); and Serpinf1, a Nf?b activator in non-muscle cells (Yabe et al., 2005). After 
differentiation into myotubes and treatment with the atrophy-inducing, synthetic glucocorticoid 
dexamethasone (Clarke et al., 2007) or empty vehicle, levels of the atrophy marker MAFbx 
were compared by qRT-PCR. Pdk4 knockdown cells expressed higher levels of MAFbx 
compared to the controls when treated with only vehicle, an effect which was enhanced in the 
presence of dexamethasone (Figure 13a-d). The opposite was observed in the case of Serpinf1, 
where knockdown cells expressed lower levels of MAFbx compared to controls. The 
dexamethasone-induced increase was also stunted in the absence of Serpinf1, though not 
completely rescued (Figure 13e-h). Together these results support the relevance of the genes 
found differentially expressed in hibernation to the muscle’s ability to reduce muscle loss not 
only in hibernation, but also in non-hibernating species. 
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Table 18. Genes differentially regulated in hibernation relate to striated muscle growth. 
Gene OMIM Summary Disease 
RASSF1 605082 Increased expression in patients with heart failure. 
Larger hearts in Rassf1 knockout mice after TAC-
surgery to induce pressure overload (Oceandy et al., 
2009). 
Heart failure, 
cardiac 
hypertrophy 
MYL3 16079 Essential myosin light chain. Mutations have been 
associated with cardiac hypertrophy and skeletal 
muscle disease (Poetter et al., 1996; Olson et al., 
2002). 
Cardiac 
hypertrophy, 
skeletal muscle 
disease 
CYC1 123980 Component of the electron transfer chain (ETC). A 
mutation in CYC1 reduces protein stability in 
muscle of a patient with growth retardation 
(Gaignard et al., 2013).  
Skeletal 
myopathy, 
growth 
retardation 
MYBPC1 160794 Myosin binding protein. Mutations are associated 
with Distal arthrogryposis type I, characterized by 
reduced muscle mass (Gurnett et al., 2010). 
Distal 
arthrogryposis 
type I, muscle 
atrophy 
TNNI3 191044 Associated with hypertrophic cardiomyopathy 
(Kimura et al., 1997).  
Hypertrophic 
cardiomyopathy 
RNF11 612598 Involved in NFKB signalling (Shembade et al., 
2009; Maddirevula et al., 2012, 11). 
n.a. 
PPIA 123840 Encodes Cyclophilin A, which is secreted in 
response to increased ROS production. Knockout 
mice have smaller hearts in response to high ROS 
levels (Satoh et al., 2011). 
n.a. 
PA2G4 602145 Knockouts are smaller with reduced circulating 
IGF-1 (Zhang et al., 2008). 
n.a. 
RORA 600825 Involved in circadian regulation and induces Bmal1 
expression (Akashi and Takumi, 2005; Sato et al., 
2004), which affects muscle function and size, 
increases PDK4 while reducing Pdha activity (Dyar 
et al., 2014). 
n.a. 
ARID5B 608538 Decreased genomic methylation has been 
associated with reduced birth weight (Engel et al., 
2014). 
n.a. 
NRG2 603818 Growth retardation in knockout mice (Britto et al., 
2004). 
n.a. 
SERPINF1 172860 Enhances NFKB signalling (Yabe et al., 2005). n.a. 
n.a.: not available 
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Figure 13: Validation of the effect of Pdk4 and Serpinf1 on muscle atrophy 
signalling in murine cells. 
(a, b) Downregulation of Pdk4 in C2C12 cells after shRNA-mediated knockdown 
was validated by immunoblot analysis with >50% reduction of Pdk4 protein levels 
(n=3, mean ± s.d., t-test). (c) Pdk4 mRNA levels are reduced by >50% as determined 
by qRT-PCR (n=3, mean ± s.e.m., t-test). (d) Knockdown of Pdk4 increases RNA 
levels the atrophy marker MAFbx and amplifies the effect of dexamethasone (Dex) 
on MAFbx. Pdk4 downregulation increases the dexamethasone effect >5-fold (n=3, 
mean ± s.e.m., two-way ANOVA, Bonferroni post-hoc test). (e-g) After shRNA 
treatment, protein and RNA levels of Serpinf1 are reduced to <20% (n=3, mean ± 
s.d./s.e.m. (protein/mRNA), t-test). (h) MAFbx mRNA levels are decreased after the 
knockdown of Serpinf1. The increase of MAFbx mRNA expression after 
dexamethasone treatment is partially reverted. (n=3, mean ± s.e.m., two-way 
ANOVA, Bonferroni post-hoc test). 
4.2 Titin’s kinase domain (TK) affects metabolic and growth signalling in 
striated muscle. 
TK regulates intracellular processes via its ability to form complexes with proteins such as 
Nbr1, p62 and Murf2 (Lange et al., 2005), but the consequence of such events on myocyte 
function have not been shown to date. To investigate its role as a signalling mediator, I 
generated a cell culture model stably expressing an inducible T7-tagged TK in C2C12 
myoblasts (Figure 14a). The construct was designed to be suppressed with doxycycline (Dox; 
Tet-OFF system; Figure 14b). However, the addition of Dox to these cells appeared to 
independently affect some of the signalling pathways we were interested in studying. 
Accordingly TK expression was not silenced in the subsequently reported experiments, and all 
results were compared between the T7-TKCD expressing cells (TK+ cells) and the parental 
controls (TK– cells) that only express the Tet-responsive element. This cell line was 
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characterized together with a TK knockout (TKKO) animal model that was generated in our 
laboratory. The animals were previously shown to exhibit macro-and microscopic changes 
including cardiac hypertrophy and a resistance to denervation-induced atrophy in skeletal 
muscle. The characterization of the cell and animal models helped build a complementary 
picture of how TK affects metabolic and trophic signalling events in the myotube as illustrated 
in the following sections.  
Figure 14: T7-tagged TKCD expression is responsive to Doxycycline (Dox) in 
the selected clone. 
(a) The double stable clone is both positive for the Neomycin and Puromycin 
resistance genes (NeoR and PuroR). (b) T7-tagged TKCD expression can be 
significantly suppressed in the presence of 5 ug/ml Dox (n=2, mean ± s.d, One-way 
ANOVA, Bonferroni post-hoc test). (c) Dox addition increases the levels of insulin-
induced pAkt (ser473) in both parental and T7-TKCD expressing cells, and the 
presence of TKCD decreases overall levels of pAkt (ser473) in C2C12 cells (n=2, 
mean ± s.d, Two-way ANOVA, Bonferroni post-hoc test). 
4.2.1 Expression of soluble titin kinase changes myocyte metabolism. 
The genes differentially expressed in the TK+ cells were used in a KEGG pathway enrichment 
analysis to obtain an overview of the processes that were affected in the presence of TK. 
Metabolic genes were the group most largely represented followed by genes of the insulin 
signalling pathway (Figure 15a). Specifically, mRNA levels of components of the pentose 
phosphate (PPP) and glycolytic pathways were elevated in the TK+ cells, while components of 
the electron transport chain (ETC) and the CO2-buffering enzyme Car13 were supressed 
(Figure 15b). The changes are summarised in relation to central glucose metabolism in 
Figure 15c. 
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Figure 15: Titin kinase (TK) alters 
glucose metabolism in C2C12 cells  
(a) KEGG pathways with which TK-
dependent mRNAs associate. (b) Relative 
change in mRNA expression levels of 
metabolic genes in the presence of TK. 
Inc.: increased, Dec.: decreased, +TK: TK-
expressing cells, NA: not applicable, +: 
activator, -: inhibitor. (c) Overview of TK-
dependent changes in pathways of central 
glucose metabolism as indicated by (b). (d, 
e) TK-expressing cells have higher levels 
of basal extracellular acidification rate 
(ECAR) as well as a higher oxygen 
consumption rate (OCR) (n=4, mean ± s.d., 
Two-way ANOVA, Bonferroni post-hoc 
test). 
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To determine whether these transcriptional changes have consequences at the functional level, 
changes in glycolysis and oxidative phosphorylation were measured and compared using a 
SeaHorse® XFe24 analyzer. We used a glycolytic stress kit, which allows the measurement of 
the changes in two parameters over time. The first parameter is the extracellular acidification 
rate (ECAR) used as a surrogate for glycolytic activity (based on the amount of lactate produced 
during glycolysis). The second parameter is the oxygen consumption rate (OCR), which reflects 
the activity of the ETC. TK+ cells kept in glucose-free medium have both higher ECAR and 
OCR, reflecting higher glycolytic and oxidative phosphorylation capacity (Figure 15d, e). Upon 
addition of 10 ?M glucose, both cell lines shift from oxidative phosphorylation to mostly 
anaerobic respiration as evident by the increase in ECAR and decrease in OCR, but TK+ cells 
maintain a slightly higher OCR, and a much higher ECAR compared to TK- cells. While the 
addition of the ATP synthase inhibitor Oligomycin (1 ?M) doesn’t affect ECAR in either cell 
type, there is a slight decrease in OCR in both cell lines reflecting a decrease in oxidative 
phosphorylation, but TK-expressing cells continue to maintain higher ECAR and OCR levels. 
The addition of 2-deoxyglucose (2-DG) at 100 x the concentration of glucose, suppresses 
ECAR in both cell types, as it is a competitive inhibitor of hexokinase, the enzyme that 
catalyses the first step in glycolysis. This confirms that the increase in ECAR is glucose-
dependent. OCR remained unaffected in either cell type, as the levels maintained post glucose-
addition are glucose-independent (Nicholls et al., 2010). These results suggest an increase in 
the rate of glycolysis and oxidative phosphorylation in TK-expressing cells. The mRNA 
expression changes of Eno1, Gapdh and Ldha are consistent with an increase in glycolysis but 
the decrease in the majority of the regulated ETC components is the opposite of the observed 
increase in OCR in the TK+ cells. 
4.2.2 Titin kinase-expressing C2C12 cells are less responsive to Insulin. 
As changes in the gene expression and pathway enrichment analyses suggested that insulin 
signalling could be perturbed in TK+ cells, they were treated with insulin after at least eight 
hours of serum-starvation and compared to TK- cells treated similarly. Levels of pAkt2 
(ser473) were measured as an output of insulin stimulation. While control cells responded 
normally to insulin, as indicated by the significant increase in pAkt (ser473) levels after 
treatment, there was no significant increase in TK-expressing cells (Figure 16a, b). Total Akt 
levels were unchanged in either cell-line (Figure.  16c, d). 
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Figure 16: TK suppresses insulin-induced Akt activation in C2C12 cells. 
(a, b) The presence of TK inhibits Akt2 phosphorylation at ser473 in response to 
insulin (n=3, mean ± s.d, Two-way ANOVA, Bonferroni post-hoc test). (c, d) Total 
levels of Akt2 are not different in TK-expressing cells (n=3, mean ± s.d., t-test). (e-
g) TK enhances Gsk3-alpha/beta phosphorylation at ser9, although total Gsk3-? 
levels are lower (n=3, mean ± s.d., t-test). 
Contrary to pAkt levels, phosphorylation of the Akt target Gsk3? was increased in TK+ cells, 
despite a decrease in total protein levels (Figure 16. e-g). Regulators of Akt phosphorylation 
were also checked including the indirect Akt phosphorylation inhibitor, PTEN, which was 
increased in TK+ cells (Figure 17 a-c). Levels of the Irs-1-binding protein and activator p62 
(Geetha et al., 2012) were decreased in these cells (Figure 17d, e), so were the levels of the Akt 
activator Igf-1 (Figure 17f, g). The changes in all three Akt upstream regulators is consistent 
with the decrease in Akt phosphorylation levels observed in these cells. 
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Figure 17: Dysregulation in insulin signalling effectors upstream of Akt in 
C2C12 cells expressing Titin kinase (TK). 
(a-c) Total PTEN levels are higher in the presence of TK (n=3, mean ± s.d., t-test). 
(d, e) p62 levels are lower in TK-expressing cells (n=3, mean ± s.d., t-test). (f, g) TK 
expression reduces Igf-1 expression on both the mRNA and protein level (n=3, mean 
± s.d., t-test). 
4.2.3 Nfkb1 is differentially regulated in Titin-kinase expressing C2C12 cells. 
The expression of TK suppressed Igf-1 mRNA and protein which argues for a TK-mediated 
change in transcription. To determine how TK might affect the transcription of Igf-1, I checked 
the transcription factor binding sites upstream of the Igf-1 gene as predicted by SA Bioscience’s 
text mining application together with the UCSD Genome browser. One of the top transcription 
sites predicted was Nf?b (Figure 18a). I then compared the changes in mRNA levels in TK+ 
cells to those in the skeletal muscle of a published Nfkb1 knockout mouse which is resistant to 
disuse atrophy (GSE23497) (Wu et al., 2011). Both datasets share a total of 19 regulated genes, 
a significant majority of which are co-regulated (p-value = 0.022, permutation test; Figure 18b). 
Among the co-regulated genes are Sgk1, Eifbp4 and Igf-2 which are involved in the Pi3k-Akt 
pathway (Taniguchi et al., 2006; Andres-Mateos et al., 2013; Manning and Cantley, 2007). This 
comparison suggests that the presence of TK decrease Nfkb1-mediated transcription. 
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Figure 18: TK affects Nfkb1 protein levels and Nfkb1-dependent expression 
patterns in C2C12 cells. 
(a) Predicted transcription factor binding sites upstream of Igf-1 include Nf?b sites 
(adopted from Qiagen's EpiTect ChIP qPCR Primer search output). (b) Nfkb1 
knockout muscle and TK-expressing cells share a significant number of coregulated 
mRNAs (p-value<10xE-6, permutation test). (c-f) Preprocessed Nfkb1 (p105) levels 
are higher in the presence of TK as are the levels of phosphorylated p50 (the 
processed form of Nfkb1), while unphosphorylated levels of p50 are less (n=3, mean 
± s.d., t-test). (g) TK increases the size of C2C12 cells (n=3, mean ± s.d., t-test). 
 
Accordingly I checked if Nfkb1 protein levels were changed in TK+ cells. Indeed, TK 
expression increased pre-processed Nfkb1 (p105) and decreased processed Nfkb1 (p50). 
Furthermore, p50 was mostly modified in TK+ cells as suggested by the increase in intensity 
of a higher Mwt band (Figure 18c-f)). Consistent with a decrease in Nfkb1-mediated atrophy 
signalling, the average cell area of TK+ cells was significantly greater than controls (Figure 
18g). 
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4.2.4 Titin kinase knockout mice (TKKO) are resistant to denervation-induced atrophy. 
Although the skeletal muscle fibres of unchallenged TKKO mice are similar in size to wildtypes 
(WT), the observed regulation of Nfkb1 in cell culture suggests the possibility of a disuse-
dependent phenotype as was reported for Nfkb1 KO mice (Hunter and Kandarian, 2004). 
Indeed denervated TKKO muscle was more resistant to atrophy than WT counterparts (Figure 
19a). To gain insight into the underlying molecular mechanism, we compared changes in the 
mRNA expression profiles of WT and TKKO skeletal muscle 2 and 14 days post-denervation 
after normalization to the innervated contralateral leg (n=3 per group). Genes significantly 
regulated in a genotype-dependent manner (Two-way ANOVA) were assigned to functional 
groups by a KEGG pathway enrichment analysis (Figure 19b). 
Figure 19: Titin kinase knockout (TKKO) muscle is resistant to denervation-
induced atrophy. 
(a) Denervated TKKO muscle is larger than wildtype (WT) as indicated by a laminin 
staining of the respective myofibers before and after sciatic nerve lesion (curtesy of 
Dr. M. Radke, unpublished). (b) KEGG pathways associated with the genes 
regulated during denervation depending on genotype during denervation as per a 
two-way ANOVA (p-value<0.05). (c) Relative change in mRNA levels of the genes 
involved in important atrophy pathways between TKKOs and WTs. Genes also 
regulated on the protein level are indicated in italics. +: activator, -: inhibitor. 
FoxO and TGF-beta signalling pathways were highly enriched and include a large subset of 
histone deacetylase (Hdac)-related genes which are not represented as an independent term in 
the KEGG database. Both pathways have previously been linked to the regulation of muscle 
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size (Sandri et al., 2004; Sartori et al., 2013). A number of Nfkb-related and ribosomal proteins 
were regulated although not significantly enriched. Changes in genes related to Nfkb-, Hdac- 
and Tgf-beta signalling, as well as ribosomal proteins are summarized in Figure 19c. Activators 
of Nfkb-signalling are expressed at lower levels in the KOs after denervation compared to 
controls while the inhibitors are decreased which is consistent with the atrophy-resistant 
phenotype. Most Hdacs are expressed at lower levels in the KOs post-denervation, while the 
Hdac-binding family of Ywha (14-3-3) proteins are increased. These proteins help sequester 
Hdacs in the cytoplasm, preventing them from localizing to nucleus, where they induce the 
expression of atrophy-inducing genes (Moresi et al., 2010). These changes are also consistent 
with a decrease in Hdac-mediated atrophy signalling in denervated KO skeletal muscle. A large 
number of ribosomal proteins and components of the TGF-pathway are expressed at higher 
levels in denervated TKKO muscle, suggesting an increase in protein translation and TGF-? 
growth signalling in the absence of TKCD in murine muscle. 
4.2.5 Nfkb/RelA, Cebpb and Xbp1 explain a large part of the Titin-kinase dependent, 
denervation-induced transcriptional changes. 
To determine which transcription factors mediate titin kinase-dependent changes in denervated 
skeletal muscle I performed separate transcription factor binding site enrichment analyses on 
the mRNA expression profiling data acquired two and 14 days after denervation. Nf?b2 was 
the only transcription factor that was regulated and had binding sites upstream a significant 
number of the genes regulated two days after denervation. 14 days after denervation, Nf?b-
binding sites were still enriched in a significant number of the regulated genes but neither Nfkb2 
nor Nfkb1 themselves were changed on the mRNA level. However, RelA (p65) - another 
member of the Nf?B transcription factor family - Cebpb and Xbp1 were regulated and also had 
a significant number of deregulated targets 14-days post-denervation. Together, the three 
transcription factors share a total of 456 targets regulated differently between KOs and WTs 14 
days after denervation (Figure 20a), explaining more than half of the transcriptional changes 
observed. 54 of these genes are targets common to all three transcription factors, and most were 
transcriptionally increased (n=35). Among the increased common targets were Tgf-? and FoxO 
signalling components Smad3, Tgfbr3 and Araf; as well as titin itself (Figure 20b). 
The observation that Nf?b-related transcription factor binding sites were enriched in genes 
regulated at both time points post denervation (Nf?b in both and RelA at 14 days) prompted a 
deeper analysis of Nf?B-dependent changes. 
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.  
Figure 20: Titin kinase alters Nfkb transcriptional activity in denervated 
muscle.  
(a) Venn diagram of the targets of the three transcription factors (TF) differentially 
regulated between WT and KO muscle 14 days after denervation. (b) The relative 
regulation of the 54 genes with TF binding sites for the three TFs in (a). (c) The 
regulation of the targets of Nf?b TFs two and 14 days post denervation reflects little 
overlap between the targets at the two time points, that RelA and Nf?b share several 
targets at 14 days and that the Nf?b components are themselves regulated in an 
Nf?b-dependent manner. Inc.: increased, Dec.: decreased, NA: not applicable, KO: 
knockout. 
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Only a small subset of the predicted Nf?b targets are regulated two and 14 days after 
denervation (n=22, corresponding to 33.3% of the targets at day two and 16.2% of those at day 
14; Figure 20c). 13 of these genes were co-regulated but none are RelA targets, while 9 were 
counter-regulated including three RelA targets. There were no targets shared between RelA at 
14 days and Nfkb at day 2 that were not also Nfkb targets at 14 days. A large number of RelA 
and Nfkb targets were shared at 14 days, all of which were coregulated. Among the Nf?b targets 
suppressed in TKKOs vs WTs two days post-denervation were RelB and Bcl3, which also 
regulate Nf?b transcription (Gilmore, 2006). RelA expression was increased in the TKKOs 
compared to controls 14 days post-denervation, while expression of the Nf?b inhibitor I?bke 
(a target of both RelA and Nfkb) was reduced. These findings suggest that the Nf?b 
transcription factors regulate their own production (Tian et al., 2005; Lombardi et al., 1995; 
Ten et al., 1992; Bren et al., 2001), in a way that decreases Bcl3 and p52/RelB-mediated 
transcription, but supports transcription mediated by RelA/p50. Genes targeted by both RelA 
and Nfkb 14 days post denervation have been associated with the regulation of striated muscle 
size such as Ankrd1 (Zhong et al., 2015) and Titin (Peng et al., 2007, 2006), which were 
increased in the knockouts as well as Fhl1 (Cowling et al., 2008), which was suppressed. In 
C2C12 cells, the Nfkb2 precursor p100 was elevated in TK+ cells, while p52 levels were not 
significantly changed (Figure 21a-c). Fhl2, a functional and structural homolog of Fhl1 (Ding 
et al., 2009) was increased in TK+ cells (Figure. 21d, e), while Hdac5 post-translational 
modification was altered as evident by the appearance of a band at a slightly lower Mwt (Figure 
22a-c). 
Figure 21: Titin kinase (TK) changes Nfkb2 and Fhl2 levels in C2C12 cells. 
(a-c) TK increases the levels of unprocessed Nfkb2 (p100), while p52 are not 
significantly different (n=3, mean ± s.d., t-test). (d, e) Fhl2 levels are higher in TK-
expressing C2C12 cells (n=3, mean ± s.d., t-test). 
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Figure 22: Titin kinase (TK) alters class II HDAC expression levels in C2C12 
cells. 
(a-c) TK decreases the levels of phosphorylated Hdac5 (upper band) in C2C12 cells 
while increasing the levels of the unphosphorylated form (lower band) (n=3, mean 
± s.d., t-test). (d, e) Total Hdac4 levels are lower in TK-expressing C2C12 cells (n=3, 
mean ± s.d., t-test). (f) HEK293 cells transiently transfected with only the catalytic 
from of TK (TKCD) have relatively lower levels of Hdac4 than those transfected 
with empty vector or the autoinhibited form (TKCDRD) while the latter have higher 
levels of Hdac4 than both TKCD and control-transfected cells (n=3, mean ± s.d., 
One-way ANOVA, Bonferroni post-hoc test). 
 
Hdac4 levels were also lower in TK+ cells (Figure 22d, e) and the same was observed in 
Hek293 cells cotransfected with Hdac4 and the catalytic domain of TK (Figure 22f).  
4.2.6 Titin kinase knockout hearts are hypertrophic and have higher levels of glucose-
derived metabolites.  
The effect of titin’s kinase domain was obvious in knockout hearts as TKKO hearts were 
significantly larger and heavier than their WT counterparts (Figure 23a, b). To investigate the 
molecular changes associated with this increase in cardiac size, I analysed Affymetrix 
expression differences between TKKOs and WTs. 100 genes were significantly regulated 
(p<0.05) between the genotypes, of which only ribosomal proteins were significantly enriched 
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as per a KEGG pathway enrichment analysis (p<0.05). All the regulated transcripts encoding 
ribosomal proteins were increased in the TKKO hearts (Rpl36, Rps12, Rps15a, Rps21, Rps24). 
The hypertrophy markers Myh6, Adrb1, and Nppa (Dorn et al., 2003) were also upregulated in 
TKKO hearts, consistent with the increase in cardiac muscle size. The gene expression analysis 
was complemented by a phospho-protein study of WT vs. KO left ventricular protein lysate 
using label-free mass spectrometry. Phosphorylation of the TK-interaction partner p62, Raptor, 
Akt2 (ser473) and Irs-1(Ser1101) were increased (Figure 23.c), suggesting elevated 
Insulin/Igf-1 signalling in TKKO hearts. In line with these changes was an increase in phospho-
Ndrg2 (Figure 23.d), a gene that was overexpressed on the mRNA and protein level in 
hibernating grizzly bear skeletal muscle (Figure 6a) and is involved in insulin-induced cardio-
protection against ischemia reperfusion injury (Sun et al., 2013). 
Figure 23: Titin kinase knockout (TKKO) hearts are hypertrophic and have a 
hyperactive Akt pathway. 
(a) TKKO hearts are larger than wildtypes (WT). (b) Unlike the different skeletal 
muscle types depicted (Q: Quadriceps; TS: Triceps Surae, TA: Tibialis Anterior), 
ventricular (V) weight of TKKOs is significantly higher than WTs (Curtesy Dr. M. 
Radke, unpublished). (c) Levels of pAkt2 (ser473) and pIrs-1 (ser1101) are 
detectable in TKKO hearts but undetected in WTs. (d) pNdrg2 levels are higher in 
TKKO hearts while (e) pGys1 levels are lower. (f) pAkt phosphorylates Ndrg2 and 
indirectly dephosphorylates Gys1. 
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The phosphorylation of Glycogen synthase (Gys1) was reduced in TKKO hearts (Figure 21e), 
which is also Akt-dependent (Manning and Cantley, 2007) (Figure 23.f). A metabolomics study 
of the same hearts used for the phospho-proteomics analysis, revealed alterations in the levels 
of several amino-acids, the majority of which were non-essential (70%). All of the affected 
NEAAs were increased in the TKKO hearts (Figure 24a-g), while the EAAs were decreased, 
except for methionine (Figure 24h-j). Lactate levels were increased in the TKKO hearts (Figure 
24k), as is later shown in skeletal muscle (Figure 25j). 
Figure 24: Amino acid and lactic acid levels are altered in Titin kinase knockout 
(TKKO) hearts. 
(a-g) Several non-essential amino acids (NEAA) are increased in TKKO hearts. 
(h-j), while two of the essential amino acids (EAA) are decreased. (k) Lactate levels 
are higher in TKKO hearts. 
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4.2.7 Glucose metabolism is deregulated in TKKO skeletal muscle. 
In C2C12 cells, titin kinase regulated not only cell size but also metabolism. To analyse if 
metabolism was also altered in TKKO skeletal muscle, mRNA expression profiles of three WT 
and three KO animals were compared (Figure 25a).  
Figure 25: Transcriptional 
deregulation of central glucose 
metabolic enzymes in titin kinase 
knockout (TKKO) skeletal muscle. 
(a) Several genes involved in central 
glucose metabolism are deregulated on 
the mRNA level in TKKO 
gastrocnemius (GA) muscle. (b) The 
genes regulated between trained WTs 
and KOs enrich to KEGG terms related 
to protein synthesis and metabolic 
deregulation among others. (c) The 
relative regulation of metabolic genes 
on the mRNA level in KOs after a 
month of training suggest an adaptive 
increase (inc.) in oxidative 
phosphorylation while TCA cycle 
enzymes remain lower (dec.). NA: not 
applicable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
71 
Indeed, several enzymes related to glucose and energy metabolism were decreased in 
unchallenged KO muscles. However the number of enzymes is not high enough to be 
significantly represented in a Gene ontology analysis. After a month of regular treadmill 
training, changes in metabolic gene expression become more evident (Figure 25b) and are for 
the most part reversed compared to the changes in unchallenged animals (Figure 25 c). For 
example components of the ETC and glycogen breakdown are higher in TKKOs, while 
expression levels of the TCA cycle enzymes remain lower in TKKOs even after training. 
Proteins regulated in TKKOs as determined by SILAC include the components of Complex I 
of the ETC Ndufa1 and Ndufv2 and several TCA proteins, all of which were decreased (Figure 
26a-e). Phkg1, the catalytic domain of the glycogen phosphorylase kinase complex and Ugp2, 
which catalyses the first step in glycogen synthesis were also decreased (Figure 26f-g). The 
enzymatic changes were complemented with an increase in glucose, lactate and malate (Figure 
26h-j) as well as glycogen. The changes in metabolites and enzymes of 
glycolysis/gluconeogenesis, TCA cycle and glycogen metabolism are summarized in Figure 
26k. These changes suggest that ATP production in TKKO muscle is lower, and glycogen 
immobilization more difficult, making these animals less capable of generating the energy 
necessary to support strenuous physical activity. 
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Figure 26 TCA cycle activity is decreased in titin kinase knockout (TKKO) 
skeletal muscle. 
(a-g) Enzymes of central glucose metabolism are decreased in the KO GA, while (h-
j) glucose, lactate and malate are increased. (k) Overlaying the protein and 
metabolite changes in TKKO muscle to central glucose metabolism indicates that 
most changes are in glycogen synthesis and breakdown, and the (Tricarboxylic acid) 
TCA cycle activity under basal activity levels. No diff.: unchanged, NA: not 
available. 
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5 Discussion 
Striated muscle size and function is regulated in response to changes in use. Muscles used 
frequently or that work against a greater load adjust by increasing their size to adapt to the 
increase in demand. The opposite is true if a muscle is used less frequently, or in adjustment to 
a decreased load. Depending on the context, a change in muscle size can be favourable or 
detrimental. For example, cardiac and skeletal muscle hypertrophy often occur in athletes 
(Scharf et al., 2010), improving their cardiac output, supporting better skeletal muscle 
oxygenation and strengthening the skeletal muscle used during exercise which improves the 
athletes’ performance over time. On the other hand, astronauts in space experiences cardiac and 
skeletal muscle atrophy, which subjects them to complications when back on Earth (LeBlanc 
et al., 1995). Skeletal muscle atrophy is common in many other situations as well, such as long-
periods of hospitalization, bone fracture, aging, muscle denervation and situations of calorie 
restriction (Glass, 2003). Increasing our understanding of muscle size regulation could thus 
help us enhance favourable and prevent detrimental changes in muscle. For this reason, a lot of 
research has been done to understand how muscle size is regulated under different conditions 
implicating a range of pathways including the Pi3k-Akt-mTor (Rommel et al., 2001), Nf?b 
(Hunter and Kandarian, 2004), Tgf-?-Bmp (Sartori et al., 2013) and HDAC/HAT (Moresi et 
al., 2010) signalling pathways. Nevertheless, pharmaceutical companies are still on the search 
for better therapeutic targets/approaches to help prevent pathological muscle atrophy and/or 
hypertrophy more efficiently, and with minimal side effects as many of these pathways have 
been associated with other functions such as cell survival, carcinogenesis, and inflammation. 
While innervation supplies stimuli about muscle use, mechanical stimulation has been shown 
to improve muscle function in patients with decreased neuroskeletal communication and 
astronauts in microgravity (Bunse et al., 2003; Layne et al., 1998). Also, hibernating bears, 
which are resistant to muscle atrophy despite a decrease in muscle load and food intake in 
winter, are able to maintain muscle mass even after denervation (Lin et al., 2012). This suggests 
innervation-independent pathways that regulate muscle size, which prompted us to study the 
molecular changes occurring in the skeletal muscle of hibernating bears, as well as in the 
muscle of mice that lack a domain, which has long been considered a mechanical sensor that 
communicates to intracellular signalling pathways.  
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5.1 Metabolic changes in hibernating and aging muscle suggest changes in NEAA 
availability that affect myotube size. 
We chose hibernating bears as a model of atrophy-resistance because - unlike small mammalian 
hibernators - bears maintain their body temperature at about 30 oC throughout hibernation while 
the small hibernators go into torpor (Carey et al., 2003). Torpor involves decreasing body 
temperatures to as low as -2 oC in some cases (Carey et al., 2003). At such low temperatures 
metabolism is largely suppressed and so is believed to play an important role in decreasing 
muscle loss in these animals. In bears, the relatively mild decrease in temperature compared to 
torpor was shown to be independent of the decrease in temperature (Tøien et al., 2011). 
According to my results, this decrease in metabolism in the muscle is attributable to a decrease 
in protein levels of a large number of metabolic enzymes. The change in these enzymes leads 
to a decrease in ATP production in muscle during hibernation according to the metabolic 
models constructed using this data. Despite the suppression of several metabolic enzymes, 
some of those affecting glycolysis and TCA cycle activity were increased, which suggests that 
they are maintained for metabolic processes besides energy production. Indeed, the models 
predict an increase in some glycolytic and TCA-cycle-derived NEAAs. Although no previous 
studies have reported a change in NEAA levels in bear skeletal muscle during hibernation, 
changes in plasma levels are known to differ (Stenvinkel et al., 2013a). On the other hand, 
according to the metabolic models generated using data from skeletal muscle of aging females, 
older female subjects with less muscle mass have lower levels of the same NEAAs that were 
increased in the metabolic model of skeletal muscle in hibernation. An example of a 
physiological condition in which NEAA concentrations were measured and associated with 
changes in skeletal muscle size include a study of ewes. In this study NEAA levels were lower 
in twin foetuses which usually have lower muscle mass than a single foetus close to birth (Sales 
et al., 2014). Together with the findings reported here, this supports the hypothesis that NEAA 
availability in skeletal muscle is associated with an increase in muscle mass. According to the 
data, in C2C12 cells, an increase in NEAA levels in muscle might not just co-occur with other 
changes that increase muscle size, but also contributes to growth, as supplementing NEAAs to 
the cells increased myotube size and suppressed the atrophy marker MAFbx. This effect is not 
necessarily due to an increase in NEAA-rich proteins as these proteins are not significantly 
increased during hibernation according to the data. It is likely that NEAAs have a role in 
atrophy signalling, as has already been shown for arginine (Jewell et al., 2015) and glutamine 
(MacLennan et al., 1987) which affect mTOR activity. mTOR mediates protein synthesis via 
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inhibiting 4ebp1 and activating ribosomal protein S6 (Figure 27). It also activates Akt by 
phosphorylation at Ser-473, which in turn suppressed FoxO1-mediated MAFbx expression, 
which could explain the decrease in MAFbx upon NEAA supplementation. 
Figure 27: Summary of trophic signalling in skeletal muscle of hibernating 
grizzly bears.  
Genes differentially regulated in hibernation vs. skeletal muscle atrophy (bold) relate 
to trophic signalling and metabolism. NEAA: non-essential amino acids; ROS: 
reactive oxygen species; TCA: Tricarboxylic acid cycle. 
 
5.2 Hibernation-specific transcriptional changes implicate Pdk4, Serpinf1 and 
insulin signalling in the regulation of muscle mass. 
The transcriptional changes occurring during hibernation helped identify genes that are 
important in controlling muscle size. By comparing the changes in mRNA levels in hibernation 
to those in several atrophy-inducing conditions we identified a group of genes that are regulated 
in the majority of the groups, some of which have already been implicated in the regulation of 
muscle size and function (Table 18). We also identified a group that was selectively regulated 
in hibernation, which I followed up on more closely. Genes regulated selectively in hibernation 
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could help explain the bear’s specific ability to maintain its mass during hibernation compared 
to humans and mice in comparable situations. Although the majority of these genes have not 
been linked to altered muscle function or size, they are co-expressed with genes that are 
important in regulating basic organ function according to a guilt-by-association approach. Two 
of the genes that have not been reported to affect muscle size include a metabolic enzyme Pdk4 
(Zhang et al., 2014) which was also regulated on the protein level and a Nfkb activator, Serpinf1 
(Yabe et al., 2005). Based on its function as an inhibitor of TCA cycle activity, Pdk4 reduces 
ROS production as it indirectly limits oxidative phosphorylation, an important source for ROS 
production in the cell (Zhang et al., 2014). A reduction in ROS production decreases protein 
damage and degradation, which would help preserve muscle mass. A reduction of Pdk4 levels 
in C2C12 cells, resulted in increased transcription of the atrophy marker MAFbx, consistent 
with an increase in protein degradation. This supports the hypothesis that during hibernation 
Pdk4 protein levels are primarily increased and that changes in mRNA levels are secondary. 
On the other hand, the reduction of Serpinf1 decreased MAFbx levels in C2C12 cells. This 
could be explained by its role as an Nfkb activator (Yabe et al., 2005). Since Nfkb signalling 
mediates disuse atrophy (Hunter and Kandarian, 2004), the loss of Serpinf1 can be expected to 
cause atrophy via decreased Nf?b activity, which increases MAFbx expression. In this scenario, 
suppressing Serpfin1 transcription could be the primary level of regulation during hibernation, 
and not necessarily secondary to changes in protein level or activity. These findings support 
the relevance of the genes regulated only in hibernation to the regulation of atrophy signalling 
in non-hibernators, but indicate that the directionality of change alone does not indicate whether 
these genes promote or inhibit atrophy. Since the regulation of these genes was driven by 
natural selection to improve the survival chances of bears during and soon after hibernation 
they potentially serve as good drug targets in therapies developed to reduce muscle loss with 
minimal side effects. The utility of biomimicry for the conservation of muscle mass has been 
demonstrated for Sgk1, which is regulated in squirrel muscle during hibernation and increases 
muscle size in mice (Andres-Mateos et al., 2013). 
In hibernating bears there were changes in a significant number of insulin signalling 
components, and all these changes reflect alterations that could enhance the pathway’s activity 
if maintained at the protein level. An increase in insulin sensitivity in muscle would be 
favourable during hibernation considering the pathway’s positive effect on muscle growth 
(Rommel et al., 2001), and argues for a tissue-specific regulation of insulin sensitivity in 
hibernation, during which circulating insulin levels are unchanged (Figure 28). Contrary to the 
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observations in muscle, adipose tissue is insulin-resistant during hibernation (Nelson et al., 
2014), facilitating lipid breakdown and increasing the availability of glycerol which is not only 
the major energy source during hibernation, but also contributes to the synthesis of non-
essential amino acids (Ahlquist et al., 1984). This keeps blood glucose levels constant, while 
decreasing the demand on muscle protein as an amino acid and energy source during the period 
of reduced caloric intake. Together, an increase in skeletal muscle sensitivity and adipose tissue 
resistance to insulin could work together to help maintain muscle mass during hibernation 
(Figure 28). 
Figure 28: Differential insulin sensitivity between adipose tissue and skeletal 
muscle in hibernating bears. 
Insulin inhibits lipolysis in adipose tissue, while stimulating glucose uptake, protein 
synthesis and muscle growth in skeletal muscle. 
 
5.3 Titin kinase regulates energy metabolism and muscle growth by modulating 
Nf?B and Akt signalling. 
The giant muscle protein titin contains a serine/threonine kinase domain that resembles the 
structure of the myosin light chain kinases (MLCK), suggesting a role in signalling (Mayans et 
al., 1998). Titin’s kinase domain rearranges when titin is stretched, exposing the catalytic core 
but not at resting forces, suggesting that it could serve as a mechanotransducer (Puchner et al., 
2008). The identification of mechanotransducers in skeletal muscle could help explain how - 
independent of neural input - muscle can adopt to changes in use (Linke, 2008). Although titin 
kinase targets and binding partners have been identified (Mayans et al., 1998; Lange et al., 
2005), little is known about the effect of titin kinase on muscle growth and metabolism or if the 
Discussion 
 
78 
kinase function is necessary for these effects. Here we show that the absence of titin kinase has 
a favourable effect on muscle size based on observations made in denervated skeletal muscle 
and hearts of mice lacking the catalytic domain of titin’s kinase region (TKKO). Transcriptional 
changes occurring in the skeletal muscle of the denervated TKKOs compared to WTs suggest 
that alterations in Nf?b, Hdac Class I and II and Tgf-? signalling occur in the absence of titin’s 
catalytic domain. Two days post-denervation a significant number of the deregulated transcripts 
in the TKKOs are potential Nf?B targets and Nfkb2 itself is decreased on the mRNA level. The 
decrease in Nfkb2 levels in the TKKO muscle could, in part, explain why TKKOs are resistant 
to denervation-induced atrophy. Nf?b transcription factors have been shown to regulate one 
another, and this is also reflected in the transcriptional changes in denervated TKKO muscle. 
The decrease in Nfkb2 early after denervation is accompanied by a decrease in its Nf?b-related 
targets RelB and Bcl3. RelB binds DNA only when dimerized with other Nf?b transcription 
factors, the most common of which is the processed Nfkb2 (p52), while Bcl3 is known to 
enhance p50-mediated transcription. Together Bcl3 and p50 are important in mediating disuse 
atrophy in muscle (Hunter and Kandarian, 2004). Thus, changes in Nfkb2 early after 
denervation help-mediate changes in other atrophy-related genes in TKKO skeletal muscle. 14 
days after denervation, Nf?b2 levels are not significantly different between WTs and KOs, but 
Nf?b transcriptional targets are nevertheless enriched. On the other hand, targets of another 
Nf?B transcription factor, RelA, are enriched at this time point and its mRNA levels are also 
increased. Unlike p50 and Bcl3, RelA does not regulate disuse (Hunter et al., 2002). And 
according to the data it is likely that RelA-p50 transcription is enhanced 14 days after 
denervation in the TKKOs, promoting the transcription of growth-associated genes (eg: 
Ankrd1, E2F3, Titin) while suppressing the transcription of atrogenes such as Fhl1 (Cowling 
et al., 2008) and the Nf?b inhibitor Ikbke (Figure 29). These genes are among the list of a 
significant number of common RelA and Nfkb targets deregulated in TKKO muscle 14 days 
after denervation. RelA also enhances its own transcription and suppress that of Hdac5, 
amplifying the RelA-dependent transcriptional changes, while suppressing Hdac5-mediated 
atrophy (Moresi et al., 2010). This suggests that changes in Hdac5 signalling might be 
secondary to changes in Nfkb transcription in TKKO skeletal muscle. However, Hdac5 was not 
the only component of Hdac signalling that was regulated in TKKO muscle. Several 14-3-3 
proteins were increased early and later after denervation in TKKOs, including 14-3-3-?, which 
was also decreased on the protein level in unchallenged TKKO muscle. These proteins are 
important in shuttling and sequestering class II Hdacs in the cytosol (Martin et al., 2007), 
preventing them from enhancing atrogene transcription. 
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Figure 29: The effect of Titin kinase (TK) on Nf?B1-mediate growth signalling. 
Upon stretch Titin kinase’s catalytic domain binds p105 preventing its processing 
into p50. Also whatever p50 is present in the cell is predominantly phosphorylated, 
increasing the avidity of p50 for DNA and enhancing the binding of p50-p50 
homodimers. Together with higher levels of Bcl3, p50-p50 activates the 
transcription of atrogenes. This decreases the chances of p65-p50 heterodimer 
formation, which is usually the predominant dimer in the cells and inhibits atrogene 
expression, while enhancing the expression of growth promoters. 
Thus, an increase in their levels in TKKO muscle could help explain its resistance to 
denervation-induced atrophy. Furthermore, Hdac2, a class I HDAC was increased in TKKO 
muscle after denervation. Unlike Hdac5, Hdac2 is mostly nuclear as it does not contain a 
nuclear export signal (NES) and is thus not affected by 14-3-3 proteins (de Ruijter et al., 2003). 
It is known to increase cardiac size in mice (Trivedi et al., 2007). An increase in the majority 
of regulated ribosomal protein-coding mRNAs in TKKO muscle suggests an increase in protein 
synthesis during denervation, while the majority of the changes in the components of the Tgf-
? pathway reflect changes that enhance signalling down this pathway. Enhanced Tgf-? 
signalling increases organ size and helps explain why TKKOs are more resistant to denervation-
induced atrophy (McPherron et al., 1997) Expression changes in Tgf-? signalling components 
such as Tgfbr3 and Smad3 14 days post-denervation are possibly mediated by Cebpb, Xbp1 
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and/or RelA as they have binding sites for all three TFs. Unlike RelA, little is known about the 
role of Xbp1 in regulating muscle size, but Cebpb interacts with RelA in modulating gene 
transcription (Xia et al., 1997), and regulates cardiac growth in response to exercise (Boström 
et al., 2010). In C2C12 cells, the expression of the catalytic domain of titin kinase increases the 
levels of unprocessed Nfkb1 and 2 (p105 and p100 respectively), and decreases the levels of 
processed Nfkb1 (p50) but only mildly affects p52 levels. The increase in p105 and p100 levels 
could be due an increase in transcription, but were unchanged according to the mRNA 
expression profiling data. Another possibility is altered processing in the presence of TK, which 
explains the accompanying decrease in the processed form of p105 (p50) and the trend seen in 
case of p52. A decrease in p50 could explain the resemblance between the mRNA expression 
profiles of Nfkb1 knockouts and TK+ cells as well as the increase in cell size compared to 
controls. Despite the decrease in p50 in the TK+ cells, the majority of it exists in a modified 
form as suggested by a higher migration band in immunoblots for the protein. One of the most 
common modifications of p50 is phosphorylation, which increases the binding affinity of p50 
for DNA (Misteli et al., 1998). In this case, DNA-binding p50 homodimers could be more 
abundant in these cells, mediating the expression of a subset of genes different to those 
regulated by p50-RelA heterodimers. Similar changes might not be detectable in the complete 
Nfkb1 KO mice, and could explain the discrepancy seen between the Nfkb1 KOs and TK+ 
cells with respect to the minor subset of counter-regulated genes. Currently little is known about 
the role of TK in regulating Nfkb1 and only with further experiments on skeletal muscle tissue 
could we get a more accurate picture of the associated changes. However, one possibility is that 
in WT muscle, the presence of titin’s kinase domain alters Nfkb1 protein levels in a way that 
promotes the formation of phospho-p50 homodimers, even if p105 processing is suppressed, 
which, together with increasing levels of Bcl3, would enhance disuse/denervation-induced 
atrophy in comparison to TKKOs. Although many of the transcriptional changes seen in the 
TKKO skeletal muscle were not detected in the C2C12 cells, some were changed on the protein 
level such as Hdac5, of which the unphosphorylated from was increased in TK+ cells. This 
suggests that TK increases the levels of unphosphorylated Hdac5, which is the form that is 
present and active in the nucleus (Martin et al., 2007). A similar change in skeletal muscle 
could help explain why muscles lacking TK are more resistant to atrophy. Another class II 
HDAC, Hdac4, was decreased in the presence of TK and no changes in migration were 
detectable suggesting that total protein levels might be lower in the presence of TK. An increase 
in Hdac4 levels alone in TKKO muscle could not explain why it is more atrophic as Class II 
knockouts have less atrophy and it is possible that Hdac4 levels are decreased in the presence 
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of TK in C2C12 cells to compensate for the increase in active Hdac5. Levels of Fhl2 are lower 
in TK- cells, while its homolog - Fhl1 - is lower on the transcriptional level in TKKOs. This 
suggests that the regulation of this family of proteins is titin kinase dependent in both systems. 
Fhl proteins 1-3 suppress growth (Ding et al., 2009). A relative decrease in Fhl protein levels 
in denervated TKKO muscle could explain why they are more resistant to atrophy compared to 
WTs.  
Unlike striated muscle, very few changes in signalling components are regulated between 
TKKO and WT hearts according to the mRNA profiling data. The largest group of regulated 
mRNAs are those that encode ribosomal proteins, which as in the denervated skeletal muscle, 
are mostly increased. Individual markers of cardiac hypertrophy such as Nppa, Myh6 and 
Adrb1 were also elevated in the TKKO hearts. On the total protein level, few changes were 
detected, while changes in Akt signalling was prominent according to changes in phospho-
protein profiles. The changes mainly reflect an increase in Akt-signalling (Figure 30). For 
example, pAkt and pIrs-1 levels were not detectable in the WTs, but measurable in TKKO 
hearts, suggesting that these phosphoproteins are increased in the absence of TK. 
Phosphorylation of Akt at ser473 is associated with an increase in activity, while the serine 
phosphorylation of Irs-1 is mostly inhibitory and Irs-1-dependent as part of a negative feedback 
loop (Taniguchi et al., 2006). These changes were also accompanied with an increase in the 
Akt-responsive protein Ndrg-2, while levels of Gys1 were decreased, an event which requires 
that Akt suppress Gsk3? by phosphorylating it at Ser9 (Manning and Cantley, 2007). Gsk3? 
however was not detected in this dataset. As increased Akt activity has been shown to increase 
organ size, these changes suggest that titin kinase suppressed Akt signalling muscle in cardiac 
muscle, which is why WT hearts are smaller than TKKOs. In C2C12 cells, TK+ cells expressed 
lower levels of pAkt upon insulin stimulation, arguing that TK suppresses insulin-induced 
signalling in these cells. This was accompanied by a decrease in the levels of the Akt-signalling 
activator Igf-1 (Rommel et al., 2001), and the Irs-1 activator p62 (Geetha et al., 2012), while 
the Akt inhibitor PTEN was decreased (Manning and Cantley, 2007). Worth noting is that p62 
was shown to exist together in a complex with the muscle specific ubiquitin ligase MuRF2 and 
TK at the sarcomeric M-band (Lange et al., 2005). This could explain why it is decreased in 
the presence of TK, which enables p62 binding to MuRF2 and its subsequent degradation 
Unlike the hearts, where pGsk3? is likely higher in the absence of TK, C2C12 cells lacking TK 
express lower levels of pGsk3?, suggesting the involvement of another Akt-like kinase in its 
regulation. One such kinase could be Sgk1 which is transcriptionally increased in the TK+, and 
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similarly increased in Nfkb1 knockout muscle. This suggests that Sgk1 up-regulation in TK+ 
cells is secondary to the decrease in p50 levels.  
Figure 30: The effect of Titin kinase (TK) on Akt signalling. 
TK suppresses Akt phosphorylation at Ser473, which leads to a decrease in pNdrg2 
levels as well as Gsk3? in KO hearts. This is accompanied by a decrease in the 
inhibitory serine phosphorylation of Irs1 as downstream effects are already in check. 
A decrease in Akt activity would also lead to a decrease in FoxO inhibition by 
phosphorylation, and consequently an increase in atrogene transcription. Also Akt 
activation of the mTORC1 complex would decreased in the presence of TK, which 
translates to a decrease in protein synthesis. A less active Akt would also means less 
Glut4 vesicle translocation to the membrane, decreasing glucose uptake in these 
cells. In C2C12 cells, Sgk1 is higher in the presence of TK overriding the effect of 
decreased Akt activity on Gsk3? and other events downstream. A decrease in pAkt 
could be due to a decrease in p62 or Igf-1 levels, an increase in PTEN or all three 
together. Names in bold correspond to signalling components that were regulated in 
the hearts or C2C12 cells in a TK-dependent manner. 
Like Akt, Sgk1 is known to increase muscle size by regulating similar downstream targets 
(Andres-Mateos et al., 2013). In fact, hibernating squirrels resist atrophy due to an increase in 
Sgk1 signalling, despite a decrease in pAkt levels (Andres-Mateos et al., 2013). No indication 
of a similar change is evident in the heart according to the different types of data generated 
from the murine hearts, which could explain the discrepancy in signal propagation beyond Akt. 
TKKO hearts also have higher levels of several NEAAs, and a decrease in two of three 
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deregulated EAAs. This suggests that NEAA also play a role in increasing cardiac size in 
TKKOs. The decrease in EAAs could be due to their increasing incorporation into proteins in 
the hypertrophic hearts, while methionine, the EAA that was increased in these hearts is taken 
up at high levels as it is essential in priming the synthesis of all new peptides. A possible 
explanation for the increase in NEAA levels in TKKO hearts is the hyperactive Akt pathway, 
which regulates the uptake of more glucose by increasing Glut4 translocation to the membrane 
(Taniguchi et al., 2006). Because the heart relies on lipid oxidation for energy generation, 
excess glucose might be shuttled towards the production of other metabolites, such as NEAAs 
or lactate, which was also notably increased in the TKKO hearts. Thus the results suggest that 
TK suppresses striated muscle growth in both hearts and skeletal muscle, but achieves that by 
regulating different pathways in the two muscle types (Figure 31). There is no difference in the 
size of TKKO and WT skeletal muscle, but the results suggest that they are less capable of 
producing of ATP. Indications to that include the decrease in several glycolytic, TCA cycle and 
respiratory chain enzymes on the mRNA and protein level in TKKO muscle. This is 
accompanied by an increase in glucose, lactate, malate and glycogen. Together these changes 
suggest that TKKO skeletal muscle cannot efficiently shuttle the pyruvate generated from 
glycolysis into the TCA cycle which decreases the amount of electron carriers generated and 
shuttled towards ATP generation via oxidative phosphorylation (Figure 32a). As a result, 
pyruvate is shuttled towards lactate or malate production, explaining why they are elevated in 
TKKO muscle. Because the amount of ATP produced in TKKO skeletal muscle is less, the 
muscle likely enhances glucose uptake to compensate, explaining the increase in glucose levels 
in the muscle. Glucose is consequently not only shuttled towards glycolysis, but also towards 
glycogen synthesis. Many of the changes in the mRNA levels of the glucose metabolic genes 
is reversed when the animals are exercised on a treadmill regularly for a month suggesting that 
exercise can rectify some of the changes in glucose metabolism, including oxidative respiration, 
and glycogen turnover. However, TCA cycle enzymes remain less in the exercised TKKOs 
arguing that TK is important for TCA cycle enzyme transcription, a function that is not 
compensated by the induction of other signalling pathways in response to increased exercise 
(muscle use). One possible mechanism by which TCA enzyme levels are regulated is via p52-
RelB. P52-RelB heterodimers are important for mitochondrial biogenesis via regulating Pgc1b 
levels (Bakkar et al., 2012). Knocking down either of these genes impairs oxidative 
phosphorylation in skeletal muscle, and since TKKO muscles have lower levels of these two 
genes, they might be incapable of transcribing Pgc1b and possibly other genes that are 
important for mitochondrial biogenesis, including TCA cycle enzymes. 
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Figure 31: Titin kinase (TK) affects different regulatory pathways in skeletal 
and cardiac muscle. 
(a) In skeletal muscle Nf?b signalling is the predominant Titin kinase effector 
pathway, affecting atrogene expression and mitochondrial biogenesis. (b) In the 
heart Akt signalling is predominantly affected by TK. In both, Hdac5 signalling is 
likely affected. 
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In C2C12 cells expressing TK, glycolytic and respiratory chain activity were both increase as 
indicated by these cells’ higher ECAR and OCR levels,. This suggests that, in this system, TK 
expression is also associated with an increase in energy production even though the changes in 
the mRNA levels of many of the respiratory chain components are decreased, which could be 
secondary to an increase in protein levels or activity in these cells (Figure 32b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Titin kinase (TK) increases ATP production in both C2C12 cells and 
murine muscle.  
(a) TK knockouts (TKKOs) have lower oxidative phosphorylation capacity than 
wildtypes (WT), so they compensate by uptaking more glucose which is mostly 
converted to glycogen and lactic acid. This decreases the amount of ATP produced 
in TKKO muscle. (b) TK expressing C2C12 cells have both more aerobic and 
anaerobic activity, which results in the production of more CO2, lactic acid and 
eventually more ATP than controls. 
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Besides the change in NEAAs, an increase in lactate is the only obviously difference in glucose-
derived metabolites in TKKO hearts. This is similar to the changes in skeletal muscle lactate 
levels. However a functional analysis done on these hearts has shown that they are similar to 
WT hearts (Dr. M. Radke, personal communication), suggesting that these hearts are capable 
of efficiently producing the energy they need to meet demands in unchallenged animals. This 
is also supported by the absence of major changes in metabolic enzyme mRNA and protein 
levels in these hearts. Also, if Nfkb signalling is not largely affected by TK in the hearts, and 
the skeletal muscle phenotype is indeed p52-RelB-dependent, the absence of TK would not be 
expected to have a great effect on the heart. Thus the data suggest that titin kinase is important 
in the regulation of ATP production in both C2C12 cells and skeletal muscle, but not so much 
in the heart. Further experiments would need to be conducted on the TKKOs to verify if the 
changes in metabolism are of functional consequence on the animals’ ability to perform 
strenuous activity compared to WTs. 
5.4 Primary and secondary effectors of titin kinase-mediated signalling. 
The initial idea behind generating a cell line expressing TK in an inducible manner was to 
facilitate the generation of time resolved data, providing insight into early (primary) and late 
(secondary) TK-dependent molecular changes. Unfortunately, preliminary experiments 
indicated a mild effect of Doxycycline - the drug used to suppress TK expression in these 
cells - on some of the signalling pathways we were interested in studying. This complicated the 
use of the system for the generation of the time resolved data, making drug-induced versus TK-
induced changes harder to discriminate. The changes reported here were all at steady, as the 
cells were used as normal stable cells in the absence of Doxycycline. Thus, a statement about 
primary and secondary effects are mostly speculative and made in context of existing 
knowledge about the Titin kinase binding partners and crosstalk between the different 
signalling pathways. 
The titin kinase as a structure is similar to the serine/threonine CaMK kinase family and has 
long been thought to be catalytically active when not inhibited by its autoregulatory domain 
that folds back on and blocks its catalytic core in the absence of stretch (Puchner et al., 2008). 
In vitro, the only substrate confirmed to be phosphorylated in a kinase-dependent manner is 
Tcap, a protein that caps titin’s N-terminus and stabilizes its integration at the Z-disc (Mayans 
et al., 1998). However, a recent report by the author of the original Tcap paper argues that what 
was reported as a titin kinase-dependent change in Tcap phosphorylation was actually an 
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artefact mediated by a contaminating kinase present in the insect cells in which TK was 
expressed, and that titin kinase itself is not catalytically active due to the presence of two non-
canonical amino acids; methionine-34 and aspartate-147 in sequences in which are mostly 
absent in active kinases (Bogomolovas et al., 2014; Lange et al., 2005). Nevertheless, titin 
kinase affects proteins binding at the M-band (Bogomolovas et al., 2014). Among the proteins 
that differentially bind at the M-band based on the presence of TK are MuRF1 and MuRF2, 
both muscle-specific ubiquitin ligases that affect protein turnover, and could explain part of the 
changes we see in the signalling pathways described in this thesis. 
The effect of Titin kinase on Akt signalling can be mainly explained via its ability to bind p62 
in a Nbr1-dependent manner (Lange et al., 2005). This interaction was shown to recruit Murf2 
to p62, an event which could lead to an increase in p62 ubiquitination and degradation. P62 
enhances Irs-1-mediated signalling, and thus enhances Akt signalling (Geetha et al., 2012). In 
the absence of TK, cells have higher levels of p62, and are capable of phosphorylating Akt 
upon insulin stimulation, a response which is dampened in the presence of TK. This is in line 
with the observations made in both animals and C2C12 cells, suggesting that this could be one 
of the primary events occurring in a TK-dependent manner. 
The effect of titin kinase on Nf?B signalling holds in both C2C12 cells and animal skeletal 
muscle. Nfkb transcription factors regulated themselves and one another, making the 
identification of a primary culprit difficult without further interaction data. However, it is likely 
that TK affects the processing of Nfkb1 from p105 to p50, which alters the amount of total p50 
as well as its DNA binding capacity (Figure 31) and subsequently alters the transcription of 
various other Nf?B signalling components, including Nfkb2, which is important for Pgc1? and 
RelB transcription. In this scenario one would imagine that TK enhances the p50 homodimer-
Bcl3 mediated disuse-atrophy response, as well as p52-RelB mediated mitochondrial 
biogenesis (Figure 32). This could explain why Nf?b1 is not deregulated on the mRNA level 
in these animals since all Nf?B-related transcriptional changes seen in the TKKOs are 
secondary to a shift in p105 processing and p50 versus phospho-p50 stoichiometry. However, 
if this is because of p105 binding TK, sequestering it from degradation or if this is secondary 
to the binding and MuRF-mediated degradation of an I?K needs to be validated by co-
immunoprecipitation experiments. In C2C12 cells, we see a decrease in the levels of Hdac4 in 
the presence of TK, which suggests that its degradation might also be regulated in a TK-MuRF 
dependent manner. Total Hdac5 levels might not be changed, with only a shift from 
phosphorylated to unphosphorylated in the presence of TK, supporting that this is not a kinase-
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dependent effect, but secondary to a change in the expression levels of a Hdac5 kinase in the 
presence of TK. Both CamkI and CamkIId are increased on the mRNA level in the TKKO 
skeletal muscle, suggesting that a decrease in their expression level in the presence of TK could 
explain the decrease in Hdac5 phosphorylation. Interestingly, Camk1 has a Nf?B binding site 
in its promoter, suggesting that its transcriptional regulation might also be Nf?b-mediated. 
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5.5 Conclusion and perspective 
This work compares how disuse atrophy is communicated in different mammalian systems. 
One of them is the hibernating grizzly bear, which is naturally resistant to disuse atrophy. By 
identifying the evolutionary changes that confer bears with the ability to maintain muscle mass, 
we hoped to identify pathways that could be harnessed for improved therapy of patients who 
suffer from muscle atrophy. Indeed, we found metabolic changes that not only suppress 
unnecessary energy expenditure in muscle during hibernation, but also enhance the production 
of non-essential amino acids, which might help prevent muscle atrophy in these animals. 
Furthermore, non-essential amino acids increase the size of cultured murine cells, suggesting 
that this treatment could support an increase in muscle mass in non-hibernating species. This is 
relevant for affordable healthcare as non-essential amino acids are, on average, cheaper than 
essential amino acids. Unlike essential amino acids, non-essential amino acids can be 
synthesized by the organism and treatments that support their production in muscle could 
improve local availability. 
In addition we identified a set of genes that are differentially expressed only during hibernation, 
and not in six other atrophy-inducing conditions in murine and human muscle, suggesting that 
these contribute to the ability of grizzly bear muscle to resist atrophy. Several of these genes 
have previously been linked to the regulation of muscle size and/or function and I show that 
two of these genes not previously associated with muscle growth affect atrophy signalling in 
murine myotubes. This further supports the relevance of this approach to extending our 
knowledge of growth regulators not only in bears but also other mammals. Indeed, we utilize 
pathways selected over thousands of years to prevent atrophy in one species to achieve the 
same in humans, while minimizing the negative effect on other critical aspects of muscle 
function. The targeting of more than one gene in combination might further improve outcome 
for patients.  
In a complementary approach to identifying growth regulators in a large animal model 
protected from disuse atrophy, we used a knockout mouse lacking the mechanically activated 
titin kinase domain to understand how muscle activity regulates growth. 
I show that the absence of this mechanosensor in murine skeletal muscle could lead to a 
decrease in ATP production, compromising the ability of these animals to perform strenuous 
physical activity. The disruption of Nf?B signalling could underlie this change in metabolic 
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activity in the absence of TK. TK-dependant changes in Nf?B signalling were also important 
in regulating muscle size in response to disuse. 
The effect on muscle growth extends to the unchallenged heart, which is bigger in the absence 
of the kinase, without additional functional consequences. The main changes in signalling in 
this case relate to Akt signalling, suggesting differences in the function of the kinase domain 
as a signalling intermediate in skeletal versus cardiac muscle (Figure 32). Together, these 
findings confirm the role of titin kinase in communicating information about muscle use and 
link titin kinase to metabolic and trophic signalling pathways. 
In summary, titin’s kinase domain is an important regulator of striated muscle signalling, which 
expands on our knowledge of how mechanical input is converted into a biochemical signal. 
The work links titin kinase to the Nf?B and Akt pathway, and shows that grizzly bear muscle 
is resistant to disuse atrophy, in part, because of its ability to modulate signalling down these 
same pathways. Importantly not only these pathways can be targeted in a clinical setting to help 
prevent muscle atrophy, but also others differentially regulated in hibernating and non-
hibernating mammals. 
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3/13 
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interacting protein 
Dex Dexamethasone 
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E  
EAA Essential amino acids 
ECAR Extracellular 
acidification rate 
EDTA Ethylenediaminetetraac
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regulated kinase-1/2 
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FDR False discovery rate 
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FN3 Fibronectin type III 
domain 
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G  
GA Gastrocnemius 
Gapdh Glyceraldehyde-3-
phosphate 
dehydrogenase 
GC Gas chromatography 
GEO Gene expression 
omnibus 
Gln Glutamine 
Glu Glutamate 
GLUT-4 Glucose transporter 
type 4 
Gly Glycine 
Gpi Glucose phosphate 
isomerase 
GRB2 Growth factor receptor 
bound protein 2 
GSK3a/b Glycogen Synthase 
kinase  type alpha/beta 
Gys1 Glycogen synthase 1 
H  
h Hour 
H/L Heavy to light ratio 
H2O Water 
HAT Histone acetyl 
transferase 
HCl Hydrochloride 
HDAC Histone deacetylase 
Hif1-alpha Hypoxia induced 
factor-1-alpha 
H.S. Horse serm 
HS/H. sapiens Homo Sapiens 
Hz Hertz 
I  
IAUCUA Institutional Animal 
Care and Use 
Committee 
IGF Insulin growth factor 
IKB Inhibitor of NFKB 
IKK IKB-kinase 
I?bke Ikb kinase e 
Ig Immunoglobulin 
INS Insulin 
IP3 Inositol tri-phosphate 
IP3R IP3-receptor 
IRS Insulin receptor 
substrate 
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L  
LC Liquid chromatography 
Ldha Lactate dehyrogenase-a 
LTQ-FT Linear ion trap 
quadrupole with 
Fourier transformation 
ion cyclotron resonance 
mass spectrometry 
LV Left ventricle 
M  
MAFbx Muscle atrophy F-box 
MAPK Mitogen activated 
protein kinase 
MCW Methanol-chloroform-
water 
min Minute 
MIRKO Muscle-insulin receptor 
knockout mice 
MLC Myosin light chain 
MLCK MLC-kinase 
MM Mus Musculus 
mRNA Messenger RNA 
MS Mass spectrometry 
mTOR Mammalian target of 
rapamycin 
mTORC1/2 Mammalian target of 
rapamycin complex 1/2 
MuRF Muscle ring-finger 
protein 
Mwt Molecular weight 
Myh6 Myosin heavy chain-6 
N  
NaCl Sodium Chloride 
NAD(H) Nicotinamide adenine 
dinucleotide 
Nbr1 Neighbour of BRCA1 
gene 1 
Ndrg2 N-Myc Downstream-
Regulated Gene 2 
Protein 
Ndufa1 NADH Dehydrogenase 
(Ubiquinone) 1 Alpha 
subcomplex, 1 
Ndufv2 NADH Dehydrogenase 
(Ubiquinone) 
Flavoprotein 2 
NEAA Non-essential amino 
acid 
NEB New England 
Biosciences 
NES Nuclear export signal 
NFKB Nuclear factor kappa-
light-chain-enhancer of 
activated B cells 
N-terminus Amino-terminus 
O  
OCR Oxygen consumption 
rate 
Ogdh ?-ketogluterate 
dehydrogenase 
OXPHOS Oxidative 
phosphorylation 
P  
P100/p52 Unprocessed/processed 
NFKB2 
P105/p50 Unprocessed/processed 
NFKB1 
P300 E1A-binding protein 
p300 
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P62 Nucleopoorin p62 
(Sequestosome 1) 
p-adj. P-value adjusted for 
multiple testing 
pAkt Phosphorylated-protein 
kinase B 
PCR Polymerase chain 
reaction 
PDH-A/B Pyruvate 
dehydrogenase  subunit 
A/B 
Pdk-3/4 Pyruvate 
dehydrogenase kinase-
3/4 
Pgc1a/b Peroxisome 
proliferator-activated 
receptor gamma 
coactivator 1-
alpha/beta 
PH Pleckstrin homology 
Phe Phenylalanine 
Phkg1 Phosphorylase kinase 
subunit gamma 1 
PI3K Phosphoinositide-3-
kinase 
PIP3 Phosphatidylinositol 3-
phosphate 
Pp1 Protein phosphatase 1 
PPAR-alpha Peroxisome 
proliferator-activated 
receptor-alpha 
ppm Parts per million 
PPP Pentose phosphate 
pathway 
Ppp1r3c Protein phosphatase 1 
regulatory subunit 3C 
Pro Proline 
PTEN Phosphatase and tensin 
homologue 
Pyg Glycogen 
phosphorylase 
Q  
qRT-PCR Quantitative real time-
PCR 
R  
RACE Rapid amplification of 
cDNA ends 
RD Regulatory domain 
REL Reticuloendotheliosis 
oncogene cellular 
homolog 
RNA Ribonucleic acid 
ROS Reactive oxygen 
species 
Rpl36 Ribosomal protein like-
36 
rpm Revolutions per minute 
Rps12/15a/21/
24 
Ribosomal protein 
subunit-12/15a/21/24 
rRNA Ribosomal RNA 
RyR Ryanodine receptor 
S  
s Second 
s.d. Standard deviation 
s.e.m. Standard error of the 
mean 
Ser Serine 
Serpinf1 Serpin peptidase 
inhibitor, clade F 
shRNA Short hairpin RNA 
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Socs Suppressor of cytokine 
signalling 
SR Sarcoplasmic reticulum 
SRF Serum response factor 
T  
TBS Tris-buffered saline 
TBS-T Tris buffered saline 
with Tween 20 
TCA Tricarboxylic acid 
Tcap Telethonine/Titin cap 
TF Transcription factor 
TFBS TF binding site 
TGF-beta Tissue growth factor-
Beta 
Thr Threonine 
TK(CD) Titin kinase catalytic 
domain 
TKCDRD Autoinhibited Titin 
kinase domain 
TWA Two-way ANOVA 
Tyr Tyrosine 
U  
UA/U.Arctos Urus Arctos 
Ugp2 UDP-Glucose 
pyrophosphorylase-2 
UPLC Ultra performance 
liquid chromatography 
US United States 
V  
V Volt 
W  
WT Wild-type 
X  
Xbp1 X-box binding protein 1
Y  
Ywha 14-3-3 protein 
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